Our experience
Нour specialists have considerable experience in all common nosologies, and also have special competence in conducting research of early phases. Use the filter to select the categories of research and services you are interested in.
Services
Year
| INN | Code | АТС | Services | Year |
|---|---|---|---|---|
| Gemcitabine | L01BC | Pyrimidine Analogues | Marketing Authorization | 2010-2012 |
| Levofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2010-2012 |
| Temozolomide | L01AX | Other Alkylating Agents | Marketing Authorization | 2010-2012 |
| Aminosalicylic acid | J04AA | Aminosalicylic Acid and Derivatives | Marketing Authorization | 2010-2012 |
| Amoxicillin + Clavulanic acid | A07EC | Aminosalicylic Acid and Similar Agents | Marketing Authorization | 2010-2012 |
| Bisoprolol | C07AB | Beta Blocking Agents, Selective | Marketing Authorization | 2010-2012 |
| Capreomycin | J04AB | Antibiotics | Marketing Authorization | 2010-2012 |
| Cycloserine | J04A | Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2010-2012 |
| Diclofenac | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | Marketing Authorization | 2010-2012 |
| Drotaverine | A03AD | Papaverine and Derivatives | Marketing Authorization | 2010-2012 |
| Epirubicin | L01DB | Anthracyclines and Related Substances | Marketing Authorization | 2010-2012 |
| Hydrochlorothiazide + Losartan | C09DA | Angiotensin II Antagonists and Diuretics | Marketing Authorization | 2010-2012 |
| Indapamide | C03BA | Sulfonamides, Plain | Marketing Authorization | 2010-2012 |
| Ketorolac | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | Marketing Authorization | 2010-2012 |
| Levofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2010-2012 |
| Meropenem | J01DH | Carbapenems | Marketing Authorization | 2010-2012 |
| Metamizole sodium + Pitofenone + Fenpiverinium bromide | N02B | Other Analgesics and Antipyretics | Marketing Authorization | 2010-2012 |
| Nebivolol | C07AB | Beta Blocking Agents, Selective | Marketing Authorization | 2010-2012 |
| Ornidazole | J01XD | Imidazole Derivatives | Marketing Authorization | 2010-2012 |
| Rabeprazole | A02BC | Proton Pump Inhibitors | Marketing Authorization | 2010-2012 |
| Anastrozole | L02BG | Enzyme Inhibitors | Marketing Authorization | 2010-2012 |
| Bisoprolol | C07AB | Beta Blocking Agents, Selective | Marketing Authorization | 2010-2012 |
| Clarithromycin | J01FA | Macrolides | Marketing Authorization | 2010-2012 |
| Glucosamine + Chondroitin sulfate Potassium Adipate + Vitamin E | M09AX | Other Drugs For Disord. Of The Musc.-Skeletal Syst | Marketing Authorization | 2010-2012 |
| Isoniazid + Pyrazinamide + Rifampicin | J04AM | Comb. Of Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2010-2012 |
| Letrozole | L02BG | Enzyme Inhibitors | Marketing Authorization | 2010-2012 |
| Levetiracetam | N03AX | Other Antiepileptics | Marketing Authorization | 2010-2012 |
| Moxifloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2010-2012 |
| Mycophenolate mofetil | L04AA | Selective Immunosuppressive Agents | Marketing Authorization | 2010-2012 |
| Nebivolol | C07AB | Beta Blocking Agents, Selective | Marketing Authorization | 2010-2012 |
| Paracetamol | N02B | Other Analgesics and Antipyretics | Marketing Authorization | 2010-2012 |
| Piperacillin + Tazobactam | J01CR | Piperacillin and Enzyme Inhibitor | Marketing Authorization | 2010-2012 |
| Rebamipide | A02BX | Other Drugs For Treatment Of Peptic Ulcer | Marketing Authorization | 2010-2012 |
| Tacrolimus | L04AD | Calcineurin inhibitors | Marketing Authorization | 2010-2012 |
| Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2010-2012 |
| Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2010-2012 |
| Aminosalicylic acid | J04AA | Aminosalicylic Acid and Derivatives | Marketing Authorization | 2013-2015 |
| Citalopram | N06AB | Serotonin Reuptake Inhibitors Selective | Marketing Authorization | 2013-2015 |
| Clopidogrel | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | Marketing Authorization | 2013-2015 |
| Cycloserine | J04A | Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2013-2015 |
| Cycloserine + Pyridoxine | J04A | Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2013-2015 |
| Cyproterone + Ethinylestradiol | G03HB | Antiandrogens and Estrogens | Marketing Authorization | 2013-2015 |
| Darunavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2013-2015 |
| Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2013-2015 |
| Gabapentin | N03AX | Other Antiepileptics | Marketing Authorization | 2013-2015 |
| Heparin | B01AB | Heparin Group | Marketing Authorization | 2013-2015 |
| Ketorolac | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | Marketing Authorization | 2013-2015 |
| Lamivudine | J05AF | Nucleoside reverse transcriptase inhibitors | Marketing Authorization | 2013-2015 |
| Lamivudine | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2013-2015 |
| Levofloxacin | J01MA | Fluoroquinolones | Bioequivalence CT | 2013-2015 |
| Moxifloxacin | J01MA | Fluoroquinolones | Bioequivalence CT | 2013-2015 |
| Nimesulide | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | Marketing Authorization | 2013-2015 |
| Sildenafil | G04BE | Drugs used in erectile dysfunction | Bioequivalence CT | 2013-2015 |
| Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2013-2015 |
| Topiramate | N03AX | Other Antiepileptics | Marketing Authorization | 2013-2015 |
| Urofollitropin | G03GA | Gonadotrophins | Marketing Authorization | 2013-2015 |
| Zidovudine + Lamivudine | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2013-2015 |
| Abacavir | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2013-2015 |
| Aminosalicylic acid | J04AA | Aminosalicylic Acid and Derivatives | Marketing Authorization | 2013-2015 |
| Atracurium besilate | M03AC | Other Quaternary Ammonium Compounds | Marketing Authorization | 2013-2015 |
| Darunavir | J05AE | HIV-proteinase inhibitors | Marketing Authorization | 2013-2015 |
| Docetaxel | L01CD | Taxanes | Marketing Authorization | 2013-2015 |
| Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Marketing Authorization | 2013-2015 |
| Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2013-2015 |
| Famciclovir | J05AB | Nucleosides and nucleotides | Bioequivalence CT | 2013-2015 |
| Imatinib | L01XE | Ингибиторы протеинкиназы | Marketing Authorization | 2013-2015 |
| Imipenem + Cilastatin | J01DH | Carbapenems | Marketing Authorization | 2013-2015 |
| Lamivudine + Zidovudine | J05AR | Antivirals for treatment of HIV infections, combination | Marketing Authorization | 2013-2015 |
| Levocetirizine | R06AE | Piperazine Derivatives | Bioequivalence CT | 2013-2015 |
| Levofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2013-2015 |
| Menotropins | G03GA | Gonadotrophins | Marketing Authorization | 2013-2015 |
| Meropenem | J01DH | Carbapenems | Marketing Authorization | 2013-2015 |
| Mesalazine | A07EC | Aminosalicylic Acid and Similar Agents | Marketing Authorization | 2013-2015 |
| Moxifloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2013-2015 |
| Moxifloxacin | J01MA | Fluoroquinolones | Phase III CT | 2013-2015 |
| Natural phospholipids | R07AA | Lung Surfactants | Marketing Authorization | 2013-2015 |
| Ofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2013-2015 |
| Paracetamol | N02B | Other Analgesics and Antipyretics | Phase III CT | 2013-2015 |
| Peginterferon | L03AB | Interferons | Phase III CT | 2013-2015 |
| Rabeprazole | A02BC | Proton Pump Inhibitors | Bioequivalence CT | 2013-2015 |
| Sulodexide | B01AB | Heparin Group | Phase III CT | 2013-2015 |
| Teicoplanin | J01XA | Glycopeptide Antibacterials | Phase III CT | 2013-2015 |
| Terizidone + Pyridoxine | J04AK | Other Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2013-2015 |
| Tobramycin | J01GB | Other Aminoglycosides | Phase III CT | 2013-2015 |
| Torasemide | C03CA | Sulfonamides, Plain | Bioequivalence CT | 2013-2015 |
| Abacavir + Lamivudine | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2013-2015 |
| Aminosalicylic acid | J04AA | Aminosalicylic Acid and Derivatives | Bioequivalence CT | 2013-2015 |
| Amoxicillin + Clavulanic acid | A07EC | Aminosalicylic Acid and Similar Agents | Bioequivalence CT | 2013-2015 |
| Ceftriaxone + Sulbactam | J01DD | Third-generation cephalosporins | Phase III CT | 2013-2015 |
| Celecoxib | M01AH | Coxibs | Bioequivalence CT | 2013-2015 |
| Cinacalcet | H05BX | Other anti-parathyroid agents | Bioequivalence CT | 2013-2015 |
| Ciprofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2013-2015 |
| Dienogest + Ethinylestradiol | G03FA | Progestogens and Estrogens, Fixed Combinations | Bioequivalence CT | 2013-2015 |
| Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Marketing Authorization | 2013-2015 |
| Efavirenz + Emtricitabine + Tenofovir | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2013-2015 |
| Erlotinib | L01XE | Protein kinase inhibitors | Marketing Authorization | 2013-2015 |
| Erlotinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2013-2015 |
| Famciclovir | J05AB | Nucleosides and nucleotides | Marketing Authorization | 2013-2015 |
| Irbesartan | C09CA | Angiotensin II Antagonists, Plain | Bioequivalence CT | 2013-2015 |
| Ivabradine | C01EB | Other Cardiac Preparations | Marketing Authorization | 2013-2015 |
| Ivabradine | C01EB | Other Cardiac Preparations | Bioequivalence CT | 2013-2015 |
| Latanoprost | S01EE | Prostaglandin analogues | Phase III CT | 2013-2015 |
| Levofloxacin | J01MA | Fluoroquinolones | Bioequivalence CT | 2013-2015 |
| Linezolid | J01XX | Other Antibacterials | Marketing Authorization | 2013-2015 |
| Linezolid | J01XX | Other Antibacterials | Bioequivalence CT | 2013-2015 |
| Linezolid | J01XX | Other Antibacterials | Phase III CT | 2013-2015 |
| Losartan + Hydrochlorothiazide | C09DA | Angiotensin II Antagonists and Diuretics | Marketing Authorization | 2013-2015 |
| Meropenem | J01DH | Carbapenems | Marketing Authorization | 2013-2015 |
| Moxifloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2013-2015 |
| Nevirapine | J05AG | Non-nucleoside reverse transcriptase inhibitors | Marketing Authorization | 2013-2015 |
| Pimecrolimus | D11AH | Agents for atopic dermatitis, excluding corticosteroids | Phase III CT | 2013-2015 |
| Pregabalin | N03AX | Other Antiepileptics | Bioequivalence CT | 2013-2015 |
| Rabeprazole | A02BC | Proton Pump Inhibitors | Marketing Authorization | 2013-2015 |
| Rabeprazole | A02BC | Proton Pump Inhibitors | Bioequivalence CT | 2013-2015 |
| Stavudine | J05AF | Nucleoside reverse transcriptase inhibitors | Marketing Authorization | 2013-2015 |
| Tenofovir + Emtricitabine | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2013-2015 |
| Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2013-2015 |
| Terizidone + Pyridoxine | J04AK | Other Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2013-2015 |
| Timolol | S01ED | Beta Blocking Agents | Marketing Authorization | 2013-2015 |
| Topiramate | N03AX | Other Antiepileptics | Marketing Authorization | 2013-2015 |
| Travoprost | S01EE | Prostaglandin analogues | Phase III CT | 2013-2015 |
| Valaciclovir | J05AB | Nucleosides and nucleotides | Bioequivalence CT | 2013-2015 |
| Valganciclovir | J05AB | Nucleosides and nucleotides | Bioequivalence CT | 2013-2015 |
| Valsartan | C09CA | Angiotensin II Antagonists, Plain | Marketing Authorization | 2013-2015 |
| Cefepime | J01DE | Fourth-generation cephalosporins | Marketing Authorization | 2016-2018 |
| Cinacalcet | H05BX | Other anti-parathyroid agents | Marketing Authorization | 2016-2018 |
| Docetaxel | L01CD | Taxanes | Phase III CT | 2016-2018 |
| Efavirenz + Emtricitabine + Tenofovir | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2016-2018 |
| Entecavir | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2016-2018 |
| Imatinib | L01XE | Ингибиторы протеинкиназы | Marketing Authorization | 2016-2018 |
| Imatinib | L01XE | Ингибиторы протеинкиназы | Bioequivalence CT | 2016-2018 |
| Irbesartan | C09CA | Angiotensin II Antagonists, Plain | Marketing Authorization | 2016-2018 |
| Lenalidomide | L04AX | Other Immunosuppressive Agents | Bioequivalence CT | 2016-2018 |
| Levocetirizine | R06AE | Piperazine Derivatives | Marketing Authorization | 2016-2018 |
| Levofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2016-2018 |
| Levofloxacin | J01MA | Fluoroquinolones | Bioequivalence CT | 2016-2018 |
| Linezolid | J01XX | Other Antibacterials | Marketing Authorization | 2016-2018 |
| Moxifloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2016-2018 |
| Nilotinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2016-2018 |
| Original drug | B01AC | Platelet Aggregation Inhibitors Excl. | Phase III CT | 2016-2018 |
| Original drug | J01DD | Third-generation cephalosporins | Phase III CT | 2016-2018 |
| Oseltamivir | J05AH | Combinations Of Antibacterials | Bioequivalence CT | 2016-2018 |
| Peginterferon alfa-2b | L03AB | Interferons | Marketing Authorization | 2016-2018 |
| Pregabalin | N03AX | Other Antiepileptics | Marketing Authorization | 2016-2018 |
| Rosuvastatin | C10AA | HMG CoA Reductase Inhibitors | Bioequivalence CT | 2016-2018 |
| Sildenafil | G04BE | Drugs used in erectile dysfunction | Marketing Authorization | 2016-2018 |
| Sildenafil | G04BE | Drugs used in erectile dysfunction | Bioequivalence CT | 2016-2018 |
| Sunitinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2016-2018 |
| Tacrolimus | L04AD | Calcineurin inhibitors | Marketing Authorization | 2016-2018 |
| Temozolomide | L01AX | Other Alkylating Agents | Bioequivalence CT | 2016-2018 |
| Tenofovir + Emtricitabine | J05AR | Antivirals for treatment of HIV infections, combination | Marketing Authorization | 2016-2018 |
| Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2016-2018 |
| Tramadol | N02AX | Other Opioids | Marketing Authorization | 2016-2018 |
| Valganciclovir | J05AB | Nucleosides and nucleotides | Marketing Authorization | 2016-2018 |
| Vancomycin | J01XA | Glycopeptide Antibacterials | Marketing Authorization | 2016-2018 |
| Abacavir + Lamivudine | J05AR | Antivirals for treatment of HIV infections, combination | Marketing Authorization | 2016-2018 |
| Abiraterone | L02BX | Other hormone antagonists and related agents | Bioequivalence CT | 2016-2018 |
| Abiraterone | L02BX | Other hormone antagonists and related agents | Marketing Authorization | 2016-2018 |
| Albendazole | P02CA | Benzimidazole Derivatives | Bioequivalence CT | 2016-2018 |
| Aminosalicylic acid | J04AA | Aminosalicylic Acid and Derivatives | Marketing Authorization | 2016-2018 |
| Bosentan | C02KX | Antihypertensives for pulmonary arterial hypertension | Bioequivalence CT | 2016-2018 |
| Capecitabine | L01BC | Pyrimidine Analogues | Bioequivalence CT | 2016-2018 |
| Celecoxib | M01AH | Coxibs | Bioequivalence CT | 2016-2018 |
| Cisplatin | L01XA | Platinum Compounds | Marketing Authorization | 2016-2018 |
| Clopidogrel | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | Marketing Authorization | 2016-2018 |
| Clopidogrel | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | Bioequivalence CT | 2016-2018 |
| Cycloserine | J04A | Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2016-2018 |
| Darunavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2016-2018 |
| Dorzolamide | S01EC | Carbonic Anhydrase Inhibitors | Marketing Authorization | 2016-2018 |
| Entecavir | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2016-2018 |
| Esomeprazole | A02BC | Proton Pump Inhibitors | Bioequivalence CT | 2016-2018 |
| Etoricoxib | M01AH | Coxibs | Bioequivalence CT | 2016-2018 |
| Etoricoxib | M01AH | Coxibs | Marketing Authorization | 2016-2018 |
| Ferric (III) hydroxide sacharose complex | B03AC | Iron, Parenteral Preparations | Marketing Authorization | 2016-2018 |
| Gefitinib | L01XX | Other Antineoplastic Agents | Bioequivalence CT | 2016-2018 |
| Iohexol | V08AB | Watersol.,Nephrotropic, Low Osm. X-Ray Contr.Media | Marketing Authorization | 2016-2018 |
| Lamivudine | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2016-2018 |
| Meloxicam | M01AC | Oxicams | Marketing Authorization | 2016-2018 |
| Montelukast | R03DC | Leukotriene receptor antagonists | Marketing Authorization | 2016-2018 |
| Mycophenolic acid | L04AA | Selective Immunosuppressive Agents | Bioequivalence CT | 2016-2018 |
| Nitrofurantoin | J01XE | Nitrofuran derivatives | Marketing Authorization | 2016-2018 |
| Ofloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2016-2018 |
| Original drug | J01DD | Third-generation cephalosporins | Marketing Authorization | 2016-2018 |
| Paracetamol + Phenylephrine + Chlorphenamine maleate | N02B | Other Analgesics and Antipyretics | Bioequivalence CT | 2016-2018 |
| Quetiapine | N05AH | Diazepines and oxazepines | Bioequivalence CT | 2016-2018 |
| Ritonavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2016-2018 |
| Rosuvastatin | C10AA | HMG CoA Reductase Inhibitors | Marketing Authorization | 2016-2018 |
| Solifenacin | G04BD | Urinary Antispasmodics | Bioequivalence CT | 2016-2018 |
| Sorafenib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2016-2018 |
| Tenofovir | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2016-2018 |
| Torasemide | C03CA | Sulfonamides, Plain | Marketing Authorization | 2016-2018 |
| Tranexamic acid | B02AA | Amino Acids | Marketing Authorization | 2016-2018 |
| Abacavir + Lamivudine + Zidovudine | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2016-2018 |
| Amoxicillin + Clavulanic acid | A07EC | Aminosalicylic Acid and Similar Agents | Marketing Authorization | 2016-2018 |
| Atazanavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2016-2018 |
| Atazanavir | J05AE | HIV-proteinase inhibitors | Marketing Authorization | 2016-2018 |
| Bendamustine | L01AA | Nitrogen Mustard Analogues | Marketing Authorization | 2016-2018 |
| Cefepime + Sulbactam | J01DE | Fourth-generation cephalosporins | Marketing Authorization | 2016-2018 |
| Ceftriaxone | J01DD | Third-generation cephalosporins | Marketing Authorization | 2016-2018 |
| Chlorambucil | L01AA | Nitrogen Mustard Analogues | Marketing Authorization | 2016-2018 |
| Cisplatin | L01XA | Platinum Compounds | Marketing Authorization | 2016-2018 |
| Dasatinib | L01XE | Ингибиторы протеинкиназы | Marketing Authorization | 2016-2018 |
| Doripenem | J01DH | Carbapenems | Marketing Authorization | 2016-2018 |
| Doxorubicin | L01DB | Anthracyclines and Related Substances | Marketing Authorization | 2016-2018 |
| Etoposide | L01CB | Podophyllotoxin Derivatives | Marketing Authorization | 2016-2018 |
| Etoricoxib | M01AH | Coxibs | Bioequivalence CT | 2016-2018 |
| Etoricoxib | M01AH | Coxibs | Marketing Authorization | 2016-2018 |
| Fingolimod | L04AA | Selective Immunosuppressive Agents | Bioequivalence CT | 2016-2018 |
| Fluorouracil | L01BC | Pyrimidine Analogues | Marketing Authorization | 2016-2018 |
| Flutamide | L02BB | Anti-Androgens | Marketing Authorization | 2016-2018 |
| Ganciclovir | J05AB | Nucleosides and nucleotides | Marketing Authorization | 2016-2018 |
| Hydroxycarbamide | L01XX | Other Antineoplastic Agents | Marketing Authorization | 2016-2018 |
| Ibrutinib | L01XE | Ингибиторы протеинкиназы | Bioequivalence CT | 2016-2018 |
| Ketorolac trometamol | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | Phase III CT | 2016-2018 |
| Lapatinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2016-2018 |
| Lenalidomide | L04AX | Other Immunosuppressive Agents | Marketing Authorization | 2016-2018 |
| Methotrexate | L01BA | Folic Acid Analogues | Marketing Authorization | 2016-2018 |
| Nifuroxazide | A07AX | Other Intestinal Antiinfectives | Marketing Authorization | 2016-2018 |
| Nilotinib | L01XE | Protein kinase inhibitors | Marketing Authorization | 2016-2018 |
| Original drug | B01AC | Platelet Aggregation Inhibitors Excl. | Marketing Authorization | 2016-2018 |
| Pantoprazole | A02BC | Proton Pump Inhibitors | Bioequivalence CT | 2016-2018 |
| Pazopanib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2016-2018 |
| Saquinavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2016-2018 |
| Sofosbuvir | J05AP | Antivirals for treatment of HCV infections | Bioequivalence CT | 2016-2018 |
| Tamoxifen | L02BA | Anti-Estrogens | Marketing Authorization | 2016-2018 |
| Telmisartan | C09CA | Angiotensin II Antagonists, Plain | Bioequivalence CT | 2016-2018 |
| Abiraterone | L02BX | Other hormone antagonists and related agents | Marketing Authorization | 2019-2020 |
| Amlodipine | C08CA | Dihydropyridine Derivatives | Marketing Authorization | 2019-2020 |
| Bleomycin | L01DC | Other Cytotoxic Antibiotics | Marketing Authorization | 2019-2020 |
| Bromhexine + Guaifenesin + Salbutamol | R05C | Expectorants,Excl Combinations With Cough Suppr. | Marketing Authorization | 2019-2020 |
| Carboplatin | L01XA | Platinum Compounds | Marketing Authorization | 2019-2020 |
| Cyclophosphamide | L01AA | Nitrogen Mustard Analogues | Marketing Authorization | 2019-2020 |
| Docetaxel | L01CD | Taxanes | Marketing Authorization | 2019-2020 |
| Donepezil | N06DA | Cholinesterase inhibitors | Marketing Authorization | 2019-2020 |
| Enoxaparin | B01AB | Heparin Group | Marketing Authorization | 2019-2020 |
| Meropenem | J01DH | Carbapenems | Marketing Authorization | 2019-2020 |
| Original drug | G01BA | Antibiotics and Corticosteroids | Phase III CT | 2019-2020 |
| Original drug | G01BA | Antibiotics and Corticosteroids | Marketing Authorization | 2019-2020 |
| Original drug | J05AX | Other Antivirals | Marketing Authorization | 2019-2020 |
| Acetylcysteine + Ambroxol | R05CB | Mucolytics | Phase III CT | 2019-2021 |
| Agomelatine | N06AX | Other Antidepressants | Bioequivalence CT | 2019-2021 |
| Ambroxol + Salbutamol + Guaifenesin | R05C | Expectorants,Excl Combinations With Cough Suppr. | Phase III CT | 2019-2021 |
| Cefepime + Sulbactam | J01DE | Fourth-generation cephalosporins | Phase III CT | 2019-2021 |
| Ethylmethylhydroxypyridine succinate | N07XX | Other Nervous System Drugs | Phase III CT | 2019-2021 |
| Olmesartan | C09CA | Angiotensin II Antagonists, Plain | Bioequivalence CT | 2019-2021 |
| Lysocime + Pyridoxine | R02AA | Antiseptics | Phase III CT | 2019-2021 |
| Pregabalin | N03AX | Other Antiepileptics | Bioequivalence CT | 2019-2021 |
| Rosuvastatin | C10AA | HMG CoA Reductase Inhibitors | Bioequivalence CT | 2019-2021 |
| Telmisartan | C09CA | Angiotensin II Antagonists, Plain | Bioequivalence CT | 2019-2021 |
| Ursodeoxycholic acid | A05AA | Bile Acid Preparations | Bioequivalence CT | 2019-2021 |
| Chlormadinone + Ethinyl Estradiol | G03AA | Progestogens and Estrogens, Fixed Combinations | Bioequivalence CT | 2019-2021 |
| Ketolorac | M01AB | Acetic Acid Derivatives and Related Substances | Phase III CT | 2019-2021 |
| Hydrocortisone acetate + Metronidazole + Natamycin + Chloramphenicol | G01BA | Antibiotics and Corticosteroids | Phase III CT | 2019-2021 |
| Etravirin | J05AG | Ненуклеозиды - ингибиторы обратной транскриптазы | Bioequivalence CT | 2019-2021 |
| Cinacalcet | H05BX | Other anti-parathyroid agents | Bioequivalence CT | 2019-2021 |
| Sunitinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2019-2021 |
| Nitisinone | A16AX | Various Alimentary Tract and Metabolism Products | Bioequivalence CT | 2019-2021 |
| Nilotinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2019-2021 |
| Lenalidomide | L04AX | Other Immunosuppressive Agents | Bioequivalence CT | 2019-2021 |
| Desloratadine | R06AX | Other Antihistamines for systemic use | Bioequivalence CT | 2019-2021 |
| Dasatinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2019-2021 |
| Acetylcysteine | R05CB | Mucolytics | Bioequivalence CT | 2019-2021 |
| Gefitinib | L01XX | Other Antineoplastic Agents | Bioequivalence CT | 2019-2021 |
| Chlorprothixen | N05AF | Thioxanthene Derivatives | Bioequivalence CT | 2019-2021 |
| Etoricoxib | M01AH | Coxibs | Bioequivalence CT | 2019-2021 |
| Vinorelbine | L01CA | Vinca alkaloids and analogues | Marketing Authorization | 2019-2021 |
| Melatonin + Glycine | N06BX | Other Psychostimulants and Nootropics | Phase III CT | 2019-2021 |
| Rabeprazole | A02BC | Proton Pump Inhibitors | Bioequivalence CT | 2019-2021 |
| Trimebutine | A03AA | Synt Anticholin,Esters With Tertiary Amino Group | Bioequivalence CT | 2019-2021 |
| Tolperisone | M02AX | Other Topical Products For Joint and Muscular Pain | Bioequivalence CT | 2019-2021 |
| Mebeverine | A03AA | Synt Anticholin,Esters With Tertiary Amino Group | Bioequivalence CT | 2019-2021 |
| Cefoperazone | J01DD | Third-generation cephalosporins | Marketing Authorization | 2019-2020 |
| Cefoxitin | J01DC | Second-generation cephalosporins | Marketing Authorization | 2019-2020 |
| Ketoanalogues of aminoacids | V06DD | Amino Acids, Incl Combinations With Polypeptides | Marketing Authorization | 2019-2020 |
| Oseltamyvir | J05AH | Neuraminidase inhibitors | Bringing dossier into the EEU complience | 2019-2020 |
| Paracetamol + Phenylephrine + Pheniramine + Ascorbic acid | N02B | Other Analgesics and Antipyretics | Marketing Authorization | 2019-2020 |
| Paracetamol + Phenylephrine + Pheniramine + Caffeine | N02B | Other Analgesics and Antipyretics | Marketing Authorization | 2019-2020 |
| Saquinavir | J05AE | HIV-proteinase inhibitors | Marketing Authorization | 2019-2020 |
| Ademetionin | A16AA | Amino Acids and Derivatives | Marketing Authorization | 2019-2021 |
| Ambroxol + Salbutamol + Guaifenesin | R05C | Expectorants,Excl Combinations With Cough Suppr. | Marketing Authorization | 2019-2021 |
| Amoxicillin + Sulbactam | J01CG | Beta-Lactamase Inhibitors | Marketing Authorization | 2019-2021 |
| Ampicillin + Sulbactam | J01CR | Comb Of Penicillins, Incl. Beta-Lactamase Inhib. | Marketing Authorization | 2019-2021 |
| Amylmetacresol + Dichlorobenzyl alcohol | R02AA | Antiseptics | Marketing Authorization | 2019-2021 |
| Anagrelide | L01XX | Other Antineoplastic Agents | Marketing Authorization | 2019-2021 |
| Aripiprazole | N05AX | Other Antipsychotics | Bioequivalence CT | 2019-2021 |
| Aripiprazole | N05AX | Other Antipsychotics | Marketing Authorization | 2019-2021 |
| Aztreonam | J01DF | Monobactams | Marketing Authorization | 2019-2021 |
| Caffeine + Paracetamol + Phenylephrine + Chlorphenamine | N02B | Other Analgesics and Antipyretics | Marketing Authorization | 2019-2021 |
| Cefepime | J01DE | Fourth-generation cephalosporins | Marketing Authorization | 2019-2021 |
| Cefoperazone + Sulbactam | J01DD | Third-generation cephalosporins | Marketing Authorization | 2019-2021 |
| Ceftriaxone + Sulbactam | J01DD | Third-generation cephalosporins | Marketing Authorization | 2019-2021 |
| Vildagliptin | A10BH | Dipeptidyl peptidase 4 (DPP-4) inhibitors | Bioequivalence CT | 2019-2021 |
| Vildagliptin + Metformin | A10BD | Biguanides and Sulfonamides In Combination | Bioequivalence CT | 2019-2021 |
| Clotrimazole | D01A | Antifungals for topical use | Marketing Authorization | 2019-2021 |
| Cyproterone | G03HA | Antiandrogens, Plain Preparations | Marketing Authorization | 2019-2021 |
| Cytisine | N07BA | Antismoking Agents | Marketing Authorization | 2019-2021 |
| Dexmedetomidine | N05CM | Other Hypnotics and Sedatives | Marketing Authorization | 2019-2021 |
| Dimetinden | R06A | Antihistamines for systemic use | Marketing Authorization | 2019-2021 |
| Diosmin + Hesperidin | C05CA | Bioflavonoids | Marketing Authorization | 2019-2021 |
| Docetaxel | L01CD | Taxanes | Marketing Authorization | 2019-2021 |
| Domperidone | A03FA | Propulsives | Marketing Authorization | 2019-2021 |
| Desogestrel + Ethinylestradiol | G03AA | Progestogens and Estrogens, Fixed Combinations | Bioequivalence CT | 2019-2021 |
| Fluvoxamine | N06AB | Serotonin Reuptake Inhibitors Selective | Marketing Authorization | 2019-2021 |
| Fosfomycin | J01XX | Other Antibacterials | Marketing Authorization | 2019-2021 |
| Gemcitabine | L01BC | Pyrimidine Analogues | Marketing Authorization | 2019-2021 |
| Ibuprofen | M01AE | Propionic Acid Derivatives | Marketing Authorization | 2019-2021 |
| Ibuprofen + Paracetamol | M01AE | Propionic Acid Derivatives | Marketing Authorization | 2019-2021 |
| Iodixanol | V08A | X-Ray Contrast Media, Iodinated | Marketing Authorization | 2019-2021 |
| Irinotecan | L01XX | Ингибиторы протеинкиназы | Marketing Authorization | 2019-2021 |
| Josamycin | J01FA | Macrolides | Marketing Authorization | 2019-2021 |
| Lysocime + Pyridoxine | R02AA | Antiseptics | Marketing Authorization | 2019-2021 |
| Metronidazole + Chlorhexidine | A01AB | Antiinfectives For Local Oral Treatment | Marketing Authorization | 2019-2021 |
| Montelukast | R03DC | Leukotriene receptor antagonists | Marketing Authorization | 2019-2021 |
| Naftifine | D01A | Antifungals for topical use | Marketing Authorization | 2019-2021 |
| Natamycin | A07AA | Antibiotics | Marketing Authorization | 2019-2021 |
| Nimesulide | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | Marketing Authorization | 2019-2021 |
| Olmesartan | C09CA | Angiotensin II Antagonists, Plain | Marketing Authorization | 2019-2021 |
| Omeprazole | A02BC | Proton Pump Inhibitors | Marketing Authorization | 2019-2021 |
| Ornidazole | J01XD | Imidazole Derivatives | Marketing Authorization | 2019-2021 |
| Ornidazole + Ciprofloxacin | J01RA | Combinations Of Antibacterials | Marketing Authorization | 2019-2021 |
| Pancreatin | A09AA | Enzyme Preparations | Marketing Authorization | 2019-2021 |
| Phosphazide | J05AF | Nucleoside reverse transcriptase inhibitors | Marketing Authorization | 2019-2021 |
| Telmisartan | C09CA | Angiotensin II Antagonists, Plain | Marketing Authorization | 2019-2021 |
| Tigecycline | J01AA | Tetracyclines | Marketing Authorization | 2019-2021 |
| Trastuzumab | L01XC | Monoclonal antibodies | Marketing Authorization | 2019-2021 |
| Adalimumab | L04AB | Tumor necrosis factor alpha (TNFα) inhibitors | Phase III CT | 2019-2021 |
| Donepezil | N06DA | Cholinesterase inhibitors | Bioequivalence CT | 2019-2021 |
| Alglucosidase alfa | A16AB | Enzymes | User testing of leaflet | 2019-2021 |
| Bortezomib | L01XX | Other Antineoplastic Agents | User testing of leaflet | 2019-2021 |
| Oxaliplatin | L01XA | Platinum Compounds | User testing of leaflet | 2019-2021 |
| Abacavir | J05AF | Nucleoside reverse transcriptase inhibitors | User testing of leaflet | 2019-2021 |
| Levonorgestrel | G03AC | 3-Oxoandrosten (4) Derivatives | User testing of leaflet | 2019-2021 |
| Cyproterone | G03HA | Antiandrogens, Plain Preparations | User testing of leaflet | 2019-2021 |
| Cyproterone | G03HA | Antiandrogens, Plain Preparations | User testing of leaflet | 2019-2021 |
| Decitabine | L01BC | Pyrimidine Analogues | User testing of leaflet | 2019-2021 |
| Insulin glargine + Lixisenatide | A10AE | Insulins and analogues, long-acting | User testing of leaflet | 2019-2021 |
| Darunavir | J05AE | HIV-proteinase inhibitors | User testing of leaflet | 2019-2021 |
| Aceclofenac | M01AB | Acetic Acid Derivatives and Related Substances | User testing of leaflet | 2019-2021 |
| Hydrochlorothiazidum + Telmisartan | C09DA | Angiotensin II Antagonists and Diuretics | User testing of leaflet | 2019-2021 |
| Lenalidomide | L04AX | Other Immunosuppressive Agents | User testing of leaflet | 2019-2021 |
| Etoricoxib | M01AH | Coxibs | User testing of leaflet | 2019-2021 |
| Telmisartan + Amlodipin | C09DB | Angiotensin II receptor blockers (ARBs) and calcium channel blockers | User testing of leaflet | 2019-2021 |
| Rosuvastatin + Valsartan | C10BX | HMG CoA reductase inhibitors, other combinations | User testing of leaflet | 2019-2021 |
| Teriflunomide | L04AA | Selective Immunosuppressive Agents | Bioequivalence CT | 2019-2021 |
| Sorafenib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2019-2021 |
| Abacavir | J05AF | Nucleoside reverse transcriptase inhibitors | Bringing dossier into the EEU complience | 2019-2021 |
| Bortezomib | L01XX | Ингибиторы протеинкиназы | Bringing dossier into the EEU complience | 2019-2021 |
| Bromhexine + Guaifenesin + Salbutamol | R05C | Expectorants,Excl Combinations With Cough Suppr. | Bringing dossier into the EEU complience | 2019-2021 |
| Darunavir | J05AE | HIV-proteinase inhibitors | Bringing dossier into the EEU complience | 2019-2021 |
| Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2019-2021 |
| Etoricoxib | M01AH | Coxibs | Bioequivalence CT | 2019-2021 |
| Adapalenum + Clindamycinum | D01A | Antifungals for topical use | Bringing dossier into the EEU complience | 2019-2021 |
| Glucoseminyl muramildipeptide | L03AX | Other Immunostimulating Agents | Bringing dossier into the EEU complience | 2019-2021 |
| Clotrimazole | D01AC | Imidazole Derivatives | Bringing dossier into the EEU complience | 2019-2021 |
| Combined herb drug | A01AD | Other Agents For Local Oral Treatment | Bioequivalence CT | 2019-2021 |
| Hydrochlorothiazidum + Telmisartan | C09DA | Angiotensin II Antagonists and Diuretics | Bioequivalence CT | 2019-2021 |
| Indapamid + Perindopril + Rosuvastatin | C10BX | HMG CoA reductase inhibitors, other combinations | Bioequivalence CT | 2019-2021 |
| Amlodipinum + Indapamidum + Perindoprilum | C09BX | Ингибиторы АПФ, другие комбинации | Bioequivalence CT | 2019-2021 |
| Darunavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2019-2021 |
| Etravirin | J05AG | Ненуклеозиды - ингибиторы обратной транскриптазы | Bioequivalence CT | 2019-2021 |
| Abacavir | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2019-2021 |
| Tenofovir | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2019-2021 |
| Posaconazole | J02AC | ;Triazole Derivatives | Bioequivalence CT | 2019-2021 |
| Teriflunomide | L04AA | Selective Immunosuppressive Agents | Bioequivalence CT | 2019-2021 |
| Mycophenolic acid | L04AA | Selective Immunosuppressive Agents | User testing of leaflet | 2019-2021 |
| Mycophenolate mofetil | L04AA | Selective Immunosuppressive Agents | User testing of leaflet | 2019-2021 |
| Drugs for treatment of hyperkalemia and hyperphosphatemia | V03AE | Drugs for treatment of hyperkalemia and hyperphosphatemia | User testing of leaflet | 2019-2021 |
| Influenza Vaccines | J07B | Influenza Vaccines | User testing of leaflet | 2019-2021 |
| Doxylamine | R06AA | Aminoalkyl Ethers | User testing of leaflet | 2019-2021 |
| Algeldrate | A02AX | Antacids | User testing of leaflet | 2019-2021 |
| Fulvestrant | L02BA | Anti-Estrogens | User testing of leaflet | 2019-2021 |
| Carvedilol | C07AG | Alpha and Beta Blocking Agents | User testing of leaflet | 2019-2021 |
| Nifedipine | C08CA | Dihydropyridine Derivatives | User testing of leaflet | 2019-2021 |
| Azithromycin | J01FA | Macrolides | User testing of leaflet | 2019-2021 |
| Ciprofloxacin | J01MA | Fluoroquinolones | User testing of leaflet | 2019-2021 |
| Lenvatinib | L01XE | Ингибиторы протеинкиназы | User testing of leaflet | 2019-2021 |
| Nimesulide | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | User testing of leaflet | 2019-2021 |
| Clopidogrel | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | User testing of leaflet | 2019-2021 |
| Desloratadine | R06AX | Other Antihistamines for systemic use | User testing of leaflet | 2019-2021 |
| immunoglobulin | L04AA | Selective Immunosuppressive Agents | User testing of leaflet | 2019-2021 |
| Amiodarone | C01BD | Antiarrhythmics, Class III | User testing of leaflet | 2019-2021 |
| Valproic acid | N03AG | Fatty Acid Derivatives | User testing of leaflet | 2019-2021 |
| Poliomyelitis Vaccines | J07BF | Poliomyelitis Vaccines | User testing of leaflet | 2019-2021 |
| Sorafenib | L01XE | Protein kinase inhibitors | User testing of leaflet | 2019-2021 |
| Vardenafil | G04BE | Drugs used in erectile dysfunction | User testing of leaflet | 2019-2021 |
| Regorafenib | L01XE | Protein kinase inhibitors | User testing of leaflet | 2019-2021 |
| Telmisartan | C09CA | Angiotensin II Antagonists, Plain | User testing of leaflet | 2019-2021 |
| Cemiplimab | L01XC | Monoclonal antibodies | User testing of leaflet | 2019-2021 |
| Vericiguat | C01DA | Organic nitrates | User testing of leaflet | 2019-2021 |
| Lenalidomide | L04AX | Other Immunosuppressive Agents | User testing of leaflet | 2019-2021 |
| Combined herb drug | A01AD | Other Agents For Local Oral Treatment | User testing of leaflet | 2019-2021 |
| Ibuprofen | M01AE | Propionic Acid Derivatives | User testing of leaflet | 2019-2021 |
| Alectinib | L01XE | Protein kinase inhibitors | User testing of leaflet | 2019-2021 |
| Rosuvastatin | C10AA | HMG CoA Reductase Inhibitors | User testing of leaflet | 2019-2021 |
| Dabigatrani etexilas | B01AA | Vitamin K Antagonists | User testing of leaflet | 2019-2021 |
| Faricimab | L01XC | Monoclonal antibodies | User testing of leaflet | 2019-2021 |
| Finerenone | С03AA | Thiazide diuretics | User testing of leaflet | 2019-2021 |
| Aducanumab | N06DX | Other anti-dementia drugs | User testing of leaflet | 2019-2021 |
| Amlodipine | C08CA | Dihydropyridine Derivatives | User testing of leaflet | 2019-2021 |
| Alirocumab | C10AX | Other Cholesterol and Triglyceride Reducers | User testing of leaflet | 2019-2021 |
| Glycopyrronii bromidum + Indacaterolum | H02AB | Glucocorticoids | User testing of leaflet | 2019-2021 |
| Agalsidase Alfa | A16AB | Enzymes | User testing of leaflet | 2019-2021 |
| Viral Vaccines | J07BX | Other Viral Vaccines | User testing of leaflet | 2019-2021 |
| Сitric acid + Potassium bicarbonate + Sodium citrate | G04BC | Urinary Concrement Solvents | User testing of leaflet | 2019-2021 |
| Benzyldimethyl-myristoilamin-propylammonium | D08AJ | Quaternary Ammonium Compounds | User testing of leaflet | 2019-2021 |
| Insulin glargine | A10AE | Insulins and analogues, long-acting | User testing of leaflet | 2019-2021 |
| Ivacaftor | R07AX | Other Respiratory System Products | User testing of leaflet | 2019-2021 |
| Clotrimazole | D01A | Antifungals for topical use | User testing of leaflet | 2019-2021 |
| Abiraterone | L02BX | Other hormone antagonists and related agents | User testing of leaflet | 2019-2021 |
| Sildenafil | G04BE | Drugs used in erectile dysfunction | User testing of leaflet | 2019-2021 |
| Vemurafenib | L01XE | Protein kinase inhibitors | User testing of leaflet | 2019-2021 |
| Thyme | R05CA | Expectorants | User testing of leaflet | 2019-2021 |
| Salmeterol + Fluticasone | R03AK | Sympathomimetics in combination with corticosteroids or other drugs, excluding anticholinergics | User testing of leaflet | 2019-2021 |
| Salbutamol sulfate | R05CB | Mucolytics | User testing of leaflet | 2019-2021 |
| Metronidazole | J01XD | Imidazole Derivatives | User testing of leaflet | 2019-2021 |
| Thiamine + Aescine | C05CX | Other Capillary Stabilizing Agents | User testing of leaflet | 2019-2021 |
| Ticagrelor | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | User testing of leaflet | 2019-2021 |
| Levodopa | N04BA | Dopa and dopa derivatives | User testing of leaflet | 2019-2021 |
| Adalimumab | L04AB | Tumor necrosis factor alpha (TNFα) inhibitors | User testing of leaflet | 2019-2021 |
| Dapagliflozin | A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | User testing of leaflet | 2019-2021 |
| Hederae folium | R05CA | Expectorants | User testing of leaflet | 2019-2021 |
| Metronidazole | A01AB | Antiinfectives For Local Oral Treatment | Bringing dossier into the EEU complience | 2022-2024 |
| Oxaliplatin | L01XA | Platinum Compounds | Bringing dossier into the EEU complience | 2022-2024 |
| Interferon y | L03AB | Interferons | Phase III CT | 2022-2024 |
| Ketoconazole + Pyrithione zinc | D01A | Antifungals for topical use | Bringing dossier into the EEU complience | 2022-2024 |
| Desloratadine | R06AX | Other Antihistamines for systemic use | Marketing Authorization | 2022-2024 |
| Tibolone | G03CX | Other estrogens | Marketing Authorization | 2022-2024 |
| Acetylcysteine | R05CB | Mucolytics | Marketing Authorization | 2022-2024 |
| Decitabine | L01BC | Pyrimidine Analogues | Marketing Authorization | 2022-2024 |
| Imipenem + Cilastatin | J01DH | Carbapenems | Marketing Authorization | 2022-2024 |
| Atosiban | G02CX | ;Gynecologicals, other | Marketing Authorization | 2022-2024 |
| Iloprost | B01AC | Platelet Aggregation Inhibitors Excl. | Marketing Authorization | 2022-2024 |
| Nimodipine | C08CA | Dihydropyridine Derivatives | Marketing Authorization | 2022-2024 |
| Dexmedetomidine | N05C | ;Hypnotics and Sedatives | Marketing Authorization | 2022-2024 |
| Teriflunomide | L04AA | Selective Immunosuppressive Agents | Marketing Authorization | 2022-2024 |
| Nitisinone | A16AX | Various Alimentary Tract and Metabolism Products | Marketing Authorization | 2022-2024 |
| Biapenem | J01DD | Third-generation cephalosporins | Marketing Authorization | 2022-2024 |
| Paclitaxel | L01CD | Taxanes | Marketing Authorization | 2022-2024 |
| Сolistimethate sodium | J01XB | Polymyxins | Marketing Authorization | 2022-2024 |
| Cinacalcet | H05BX | Other anti-parathyroid agents | Marketing Authorization | 2022-2024 |
| Gadodiamide | V08CA | Paramagnetic Contrast Media | Marketing Authorization | 2022-2024 |
| Dantrolene | M03CA | Dantrolene and Derivatives | Marketing Authorization | 2022-2024 |
| Ertapenem | J01DH | Carbapenems | Marketing Authorization | 2022-2024 |
| Bromhexine + Guaifenesin + Salbutamol | R05C | Expectorants,Excl Combinations With Cough Suppr. | Marketing Authorization | 2022-2024 |
| Vancomycin | J01XA | Glycopeptide Antibacterials | Marketing Authorization | 2022-2024 |
| Tiepenem | J01DH | Carbapenems | Marketing Authorization | 2022-2024 |
| Aminoacids for parenteral nutrition | A16AA | Amino Acids and Derivatives | Bringing dossier into the EEU complience | 2022-2024 |
| Adapalenum + Clindamycinum | D10AD | Antifungals for topical use | Bringing dossier into the EEU complience | 2022-2024 |
| Dabigatrani etexilas | B01AA | Vitamin K Antagonists | Bioequivalence CT | 2022-2024 |
| Apixaban | B01AF | Other Antithrombotic Agents | Bioequivalence CT | 2022-2024 |
| Dapagliflozin | A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | Bioequivalence CT | 2022-2024 |
| Tilorone | J05AX | Other Antivirals | Bioequivalence CT | 2022-2024 |
| Salmeterol + Fluticasone | R03AK | Sympathomimetics in combination with corticosteroids or other drugs, excluding anticholinergics | User testing of leaflet | 2022-2024 |
| Sitagliptin | A10BH | Dipeptidyl peptidase 4 (DPP-4) inhibitors | User testing of leaflet | 2022-2024 |
| Perampanel | N03A | Other Antiepileptics | User testing of leaflet | 2022-2024 |
| Glycopyrronii bromidum | H02AB | Glucocorticoids | User testing of leaflet | 2022-2024 |
| Baloxavir marboxil | J05AX | Other Antivirals | User testing of leaflet | 2022-2024 |
| Plerixafor | L03AX | Other Immunostimulating Agents | User testing of leaflet | 2022-2024 |
| Herbal drug | R07AX | Other Respiratory System Products | User testing of leaflet | 2022-2024 |
| Cobimetinib | L01XE | Protein kinase inhibitors | User testing of leaflet | 2022-2024 |
| Herbal drug | A03AX | Other Synthetic Anticholinergic Agents | User testing of leaflet | 2022-2024 |
| Polyvitamine | A11BA | Multivitamins, Plain | Bringing dossier into the EEU complience | 2022-2024 |
| Erlotinib | L01XE | Protein kinase inhibitors | Marketing Authorization | 2022-2024 |
| Paliperidone | N05AX | ;Other Antipsychotics | Marketing Authorization | 2022-2024 |
| Mometasone | D07AC | Corticosteroids, Potent (Group III) | Marketing Authorization | 2022-2024 |
| Diclofenac | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | Bringing dossier into the EEU complience | 2022-2024 |
| Amylmetacresol + Dichlorobenzyl alcohol | R02AA | Antiseptics | Bringing dossier into the EEU complience | 2022-2024 |
| Ademetionin | A16AA | Amino Acids and Derivatives | Marketing Authorization | 2022-2024 |
| Piperacillin + Tazobactam | J01CR | Piperacillin and Enzyme Inhibitor | Marketing Authorization | 2022-2024 |
| Cabazitaxel | L01CD | Taxanes | Marketing Authorization | 2022-2024 |
| Cefoperazone + Sulbactam | J01DD | Third-generation cephalosporins | Marketing Authorization | 2022-2024 |
| Rivaroxaban | B01AF | Direct factor Xa inhibitors | Bioequivalence CT | 2022-2024 |
| Lapatinib | L01XE | Protein kinase inhibitors | Bioequivalence CT | 2022-2024 |
| Telmisartan + Amlodipin | C09DB | Angiotensin II receptor blockers (ARBs) and calcium channel blockers | Bioequivalence CT | 2022-2024 |
| Raltegravir | J05AX | Other Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2022-2024 |
| Darunavir | J05AE | HIV-proteinase inhibitors | Bioequivalence CT | 2022-2024 |
| Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2022-2024 |
| Salmeterolum+ Fluticasonum | R03AK | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergicsAdrenergics in combination with corticosteroids or other drugs, excl. Anticholinergics | User testing of leaflet | 2022-2024 |
| Sitagliptin | A10BD | Biguanides and Sulfonamides In Combination | User testing of leaflet | 2022-2024 |
| Perampanel | N03AX | Other Antiepileptics | User testing of leaflet | 2022-2024 |
| Glycopyrronium bromide | R03AL | Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
User testing of leaflet | 2022-2024 |
| Vildagliptin | A10BH | Dipeptidyl peptidase 4 (DPP-4) inhibitors | User testing of leaflet | 2022-2024 |
| Vildagliptin + Metformin | A10BD | Biguanides and Sulfonamides In Combination | User testing of leaflet | 2022-2024 |
| Fondaparinux sodium | B01AX | ;Other Antithrombotic Agents | User testing of leaflet | 2022-2024 |
| Rivaroxaban | B01AF | Direct factor Xa inhibitors | User testing of leaflet | 2022-2024 |
| Amlodipinum + Perindoprilum + Rosuvastatinum | C10BX | HMG CoA reductase inhibitors, other combinations | User testing of leaflet | 2022-2024 |
| Dexketoprofen | M01AE | Propionic Acid Derivatives | User testing of leaflet | 2022-2024 |
| Dimetinden | R06A | Antihistamines for systemic use | User testing of leaflet | 2022-2024 |
| Dienogest | G03FA | Progestogens and Estrogens, Fixed Combinations | User testing of leaflet | 2022-2024 |
| Mometasone furoate | D07AC | Corticosteroids, Potent (Group III) | User testing of leaflet | 2022-2024 |
| Oseltamivir | J05AH | Combinations Of Antibacterials | User testing of leaflet | 2022-2024 |
| Fludarabine | L01BB | Purine analogues | User testing of leaflet | 2022-2024 |
| Drospirenonum+ Oestrogen | G03AA | Progestogens and estrogens, fixed combinations | User testing of leaflet | 2022-2024 |
| Riociguat | С02KX | Antihypertensives for pulmonary arterial hypertension | User testing of leaflet | 2022-2024 |
| Cemiplimab | L01XC | Monoclonal antibodies | User testing of leaflet | 2022-2024 |
| Zinc sulfate | A12CB | ;Zincum | User testing of leaflet | 2022-2024 |
| Desloratadine | R06AX | Other Antihistamines for systemic use | User testing of leaflet | 2022-2024 |
| Metronidazole | J01XD | Imidazole Derivatives | User testing of leaflet | 2022-2024 |
| Telmisartan | C09CA | Angiotensin II Antagonists, Plain | User testing of leaflet | 2022-2024 |
| Ipidacrine | N06DA | Anticholinesterases | User testing of leaflet | 2022-2024 |
| Insulin | A10AB | Insulins and analogues for injection, fast-acting | User testing of leaflet | 2022-2024 |
| Torasemide | C03CA | Sulfonamides, Plain | User testing of leaflet | 2022-2024 |
| Trimebutine | A03AA | Synt Anticholin,Esters With Tertiary Amino Group | User testing of leaflet | 2022-2024 |
| Ibuprofen | M01AE | Propionic Acid Derivatives | User testing of leaflet | 2022-2024 |
| Pyridoxine | A11HA | Other plain vitamin preparations | User testing of leaflet | 2022-2024 |
| Cardui mariae fructus | A05AX | Other Drugs For Bile Therapy | User testing of leaflet | 2022-2024 |
| Tacrolimus | L04AD | Calcineurin inhibitors | User testing of leaflet | 2022-2024 |
| Cidofovir | J05AB | Nucleosides and nucleotides | User testing of leaflet | 2022-2024 |
| Naproxen | M01AE | Propionic Acid Derivatives | User testing of leaflet | 2022-2024 |
| Emicizumab | B02BX | Other systemic hemostatics | User testing of leaflet | 2022-2024 |
| Salbutamol | R03AC | Selective beta-2-adrenoreceptor agonists | User testing of leaflet | 2022-2024 |
| Ambroxol | R05CB | Mucolytics | User testing of leaflet | 2022-2024 |
| Obinutuzumab | L01FA | ;CD20 (Clusters of Differentiation 20) inhibitors | User testing of leaflet | 2022-2024 |
| Losartan | C09DA | Angiotensin II Antagonists and Diuretics | User testing of leaflet | 2022-2024 |
| Faricimab | L01XC | Monoclonal antibodies | User testing of leaflet | 2022-2024 |
| Ticagrelor | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | Bioequivalence CT | 2022-2024 |
| Vildagliptin | A10BH | Dipeptidyl peptidase 4 (DPP-4) inhibitors | Bioequivalence CT | 2022-2024 |
| Areplivir | J05AX | Other Antivirals | Bioequivalence CT | 2022-2024 |
| Ceftibuten | J01DD | Third generation cephalosporins | Bioequivalence CT | 2022-2024 |
| Palbociclib | L01EF | Cyclin-dependent kinase (CDK) inhibitors | Bioequivalence CT | 2022-2024 |
| Emtricitabine | J05AF | Nucleoside reverse transcriptase inhibitors | Bioequivalence CT | 2022-2024 |
| Amlodipinum + Indapamidum + Perindoprilum | C09BX | Ингибиторы АПФ, другие комбинации | Marketing Authorization | 2022-2024 |
| Hydrochlorothiazidum + Telmisartan | C09DA | Angiotensin II Antagonists and Diuretics | Marketing Authorization | 2022-2024 |
| Dabigatrani etexilas | B01AA | Vitamin K Antagonists | Marketing Authorization | 2022-2024 |
| Amoxicillin + Sulbactam | J01CG | Beta-Lactamase Inhibitors | Marketing Authorization | 2022-2024 |
| Ampicillin + Sulbactam | J01CR | Comb Of Penicillins, Incl. Beta-Lactamase Inhib. | Marketing Authorization | 2022-2024 |
| Sulbactam | J01DD | Third-generation cephalosporins | Marketing Authorization | 2022-2024 |
| Lansoprazole | A02BD | Other Drugs For Treatment Of Peptic Ulcer | Marketing Authorization | 2022-2024 |
| Omeprazole | A02BC | Proton Pump Inhibitors | Marketing Authorization | 2022-2024 |
| Rabeprazole | A02BC | Proton Pump Inhibitors | Marketing Authorization | 2022-2024 |
| Pantoprazole | A02BC | Proton Pump Inhibitors | Marketing Authorization | 2022-2024 |
| Tigecycline | J01AA | Tetracyclines | Marketing Authorization | 2022-2024 |
| Esomeprazole | A02BC | Proton Pump Inhibitors | Marketing Authorization | 2022-2024 |
| Micafungin | J02AX | Other Antimycotics for systemic use | Marketing Authorization | 2022-2024 |
| Fondaparinux sodium | B01AX | ;Other Antithrombotic Agents | Marketing Authorization | 2022-2024 |
| Cefepime + Sulbactam | J01DE | Fourth-generation cephalosporins | Marketing Authorization | 2022-2024 |
| Fat Emulsions For Parenteral Nutrition | B05BA | Solutions For Parenteral Nutrition | Marketing Authorization | 2022-2024 |
| Olmesartan + Amlodipine + Hydrochlorothiazide | C09DB | Angiotensin II receptor blockers (ARBs) and calcium channel blockers | Marketing Authorization | 2022-2024 |
| Gemcitabine | L01BC | Pyrimidine Analogues | Marketing Authorization | 2022-2024 |
| Polyvitamine | A11BA | Multivitamins, Plain | Marketing Authorization | 2022-2024 |
| Vancomycin | J01XA | Glycopeptide Antibacterials | Marketing Authorization | 2022-2024 |
| Sodium glycerophosphate | B05XA | Electrolyte solutions | Marketing Authorization | 2022-2024 |
| Salbutamol | R03AC | Selective beta-2-adrenoreceptor agonists | Marketing Authorization | 2022-2024 |
| Carfilzomib | L01XG | Proteasome inhibitors | Marketing Authorization | 2022-2024 |
| Doripenem | J01DH | Carbapenems | Marketing Authorization | 2022-2024 |
| Tadalafil | G04BE | Drugs used in erectile dysfunction | Marketing Authorization | 2022-2024 |
| Caffeine + Paracetamol + Phenylephrine + Chlorphenamine | N02B | Other Analgesics and Antipyretics | Marketing Authorization | 2022-2024 |
| Fedratinib | L01EJ | Lipid kinase inhibitors | Marketing Authorization | 2022-2024 |
| Azacitidine | L01BC | ;Pyrimidine Analogues | Marketing Authorization | 2022-2024 |
| Deucravacitinib | L04AA | Selective Immunosuppressive Agents | Marketing Authorization | 2022-2024 |
| Clotrimazole | D01A | Antifungals for topical use | Bringing dossier into the EEU complience | 2022-2024 |
| Combined herb drug | A01AD | Other Agents For Local Oral Treatment | Bringing dossier into the EEU complience | 2022-2024 |
| Beta-alanine |
G02CX | Gynecologicals, other | Bringing dossier into the EEU complience | 2022-2024 |
| Bromhexine + Guaifenesin + Salbutamol | R05C | Expectorants,Excl Combinations With Cough Suppr. | Bringing dossier into the EEU complience | 2022-2024 |
| Clotrimazolum+Metronidazolum | G01AF | Imidazole Derivatives | Bringing dossier into the EEU complience | 2022-2024 |
| Mometasone | D07AC | Corticosteroids, Potent (Group III) | Bringing dossier into the EEU complience | 2022-2024 |
| Amolorfine | D01AE | ;Other Antifungals for topical use | Bringing dossier into the EEU complience | 2022-2024 |
| Imiquimod | D06BB | Antivirals | Bringing dossier into the EEU complience | 2022-2024 |
| Tibolone | G03CX | Other estrogens | User testing of leaflet | 2022-2024 |
| Ceftriaxone + Sulbactam | J01DD | Third-generation cephalosporins | User testing of leaflet | 2022-2024 |
| Valsartan + Amlodipine + Hydrochlorothiazide | C09DX | Angiotensin II antagonists, other combinations | User testing of leaflet | 2022-2024 |
| Anifrolumab | L01FX | Прочие моноклональные антитела | User testing of leaflet | 2022-2024 |
| Entrectinib | L01XE | Protein kinase inhibitors | User testing of leaflet | 2022-2024 |
| Satralizumab | L04AC | Interleukin inhibitors | User testing of leaflet | 2022-2024 |
| Melphalan | L01AA | Nitrogen Mustard Analogues | User testing of leaflet | 2022-2024 |
| Viral Vaccines | J07BX | Other Viral Vaccines | User testing of leaflet | 2022-2024 |
| Trientine | A16AX | Various Alimentary Tract and Metabolism Products | User testing of leaflet | 2022-2024 |
| Ambroxol + Salbutamol + Guaifenesin | R05C | Expectorants,Excl Combinations With Cough Suppr. | User testing of leaflet | 2022-2024 |
| Doxylamine hydrosuccinas | R06AA | Aminoalkyl Ethers | User testing of leaflet | 2022-2024 |
| Glimepiride | A10BB | ;Sulfonamides, Urea Derivatives | User testing of leaflet | 2022-2024 |
| Lozartan | C09CA | Angiotensin II Antagonists, Plain | User testing of leaflet | 2022-2024 |
| Laronidase | A16AB | Enzymes | User testing of leaflet | 2022-2024 |
| Vismodegib | L01XJ | Hedgehog pathway inhibitors | User testing of leaflet | 2022-2024 |
| Salbutamol | R03AC | Selective beta-2-adrenoreceptor agonists | User testing of leaflet | 2022-2024 |
| Sulbactam | J01DD | Third-generation cephalosporins | User testing of leaflet | 2022-2024 |
| Busulfan | L01AB | Alkyl Sulphonates | User testing of leaflet | 2022-2024 |
| Riamilovir | J05AX | Other Antivirals | User testing of leaflet | 2022-2024 |
| Аmorolfine | D01AE | ;Other Antifungals for topical use | User testing of leaflet | 2022-2024 |
| Valsartan | C09CA | Angiotensin II Antagonists, Plain | User testing of leaflet | 2022-2024 |
| Valsartan + Hydrochlorothiazide | C09DA | Angiotensin II Antagonists and Diuretics | User testing of leaflet | 2022-2024 |
| Levofloxacin | J01MA | Fluoroquinolones | User testing of leaflet | 2022-2024 |
| Дименгидринат | R06AX | Other Antihistamines for systemic use | User testing of leaflet | 2022-2024 |
| Moxonidine | C02AC | Imidazoline Receptor Agonists | User testing of leaflet | 2022-2024 |
| Combined herb drug | С04ВХ | Other Urologicals | User testing of leaflet | 2022-2024 |
| Fosfomycin | J01XX | Other Antibacterials | User testing of leaflet | 2022-2024 |
| Pertuzumab | L01FD | HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors | User testing of leaflet | 2022-2024 |
| Xylometazoline | R01AA | Sympathomimetics, Plain | User testing of leaflet | 2022-2024 |
| Cefodizimum | J01DD | Third-generation cephalosporins | User testing of leaflet | 2022-2024 |
| Trastuzumab emtansine | L01FD | HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors | User testing of leaflet | 2022-2024 |
| Cefepime + Sulbactam | J01DE | Fourth-generation cephalosporins | User testing of leaflet | 2022-2024 |
| Cetirizine | R06AE | Piperazine Derivatives | User testing of leaflet | 2022-2024 |
| Alglucosidase alfa | A16AB | Enzymes | User testing of leaflet | 2022-2024 |
| Valproic acid | N03AG | Fatty Acid Derivatives | User testing of leaflet | 2022-2024 |
| Valproate sodium | N03AG | Fatty Acid Derivatives | User testing of leaflet | 2022-2024 |
| Hydrochlorothiazide | C03AA | Thiazides, Plain | User testing of leaflet | 2022-2024 |
| Finerenone | C03DA | Aldosterone Antagonists | User testing of leaflet | 2022-2024 |
| Valsartan + Indapamide | C09DA | Angiotensin II Antagonists and Diuretics | User testing of leaflet | 2022-2024 |
| Azithromycin | J01FA | Macrolides | Bringing dossier into the EEU complience | 2022-2024 |
| Anagrelide | L01XX | Other Antineoplastic Agents | Bringing dossier into the EEU complience | 2022-2024 |
| Аmorolfine | D01AE | ;Other Antifungals for topical use | Bringing dossier into the EEU complience | 2022-2024 |
| Gadodiamide | V08CA | Paramagnetic Contrast Media | Bringing dossier into the EEU complience | 2022-2024 |
| Gemcitabine | L01BC | Pyrimidine Analogues | Bringing dossier into the EEU complience | 2022-2024 |
| Glucoseminyl muramildipeptide | L03AX | Other Immunostimulating Agents | Bringing dossier into the EEU complience | 2022-2024 |
| Dantrolene | M03CA | Dantrolene and Derivatives | Bringing dossier into the EEU complience | 2022-2024 |
| Dexmedetomidine | N05CM | Other Hypnotics and Sedatives | Bringing dossier into the EEU complience | 2022-2024 |
| Dextromethorphanum+ Paracetamolum + Phenylephrinum+ Chlorphenaminum | N02BE | ;Anilides | Bringing dossier into the EEU complience | 2022-2024 |
| Fat Emulsions For Parenteral Nutrition | B05BA | Solutions For Parenteral Nutrition | Bringing dossier into the EEU complience | 2022-2024 |
| Ipratropium bromide + Fenoterol | R03AL | Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
Bringing dossier into the EEU complience | 2022-2024 |
| Iodixanol | V08AB | Watersol.,Nephrotropic, Low Osm. X-Ray Contr.Media | Bringing dossier into the EEU complience | 2022-2024 |
| Kalii acetas + Calcii acetas + Magnii acetas + Natrii acetas + Natrii chloridum | B05BB | Solutions Affecting The Electrolyte Balance | Bringing dossier into the EEU complience | 2022-2024 |
| Carboplatin | L01XA | Platinum Compounds | Bringing dossier into the EEU complience | 2022-2024 |
| Clotrimazolum | G01AF | Imidazole Derivatives | Bringing dossier into the EEU complience | 2022-2024 |
| Immunostimulator | L03AX | Other Immunostimulating Agents | Bringing dossier into the EEU complience | 2022-2024 |
| Meglumini acridоnacetas | L03AX | Other Immunostimulating Agents | Bringing dossier into the EEU complience | 2022-2024 |
| Mometasone | D07AC | Corticosteroids, Potent (Group III) | Bringing dossier into the EEU complience | 2022-2024 |
| Azelastinum + Mometasonum | H02BX | Corticosteroids for systemic use, Combinations | Bringing dossier into the EEU complience | 2022-2024 |
| Nimesulide | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | Bringing dossier into the EEU complience | 2022-2024 |
| Temozolomide | L01AX | Other Alkylating Agents | Bringing dossier into the EEU complience | 2022-2024 |
| Teriflunomide | L04AA | Selective Immunosuppressive Agents | Bringing dossier into the EEU complience | 2022-2024 |
| Tigecycline | J01AA | Tetracyclines | Bringing dossier into the EEU complience | 2022-2024 |
| Tizanidine | M03BX | Other Centrally Acting Agents | Bringing dossier into the EEU complience | 2022-2024 |
| Famciclovir | J05AB | Nucleosides and nucleotides | Bringing dossier into the EEU complience | 2022-2024 |
| Phosphazide | J05AF | Nucleoside reverse transcriptase inhibitors | Bringing dossier into the EEU complience | 2022-2024 |
| Cefuroxime | J01RA | Combinations Of Antibacterials | Bringing dossier into the EEU complience | 2022-2024 |
| Cinacalcet | H05BX | Other anti-parathyroid agents | Bringing dossier into the EEU complience | 2022-2024 |
| Cytisine | N07BA | Antismoking Agents | Bringing dossier into the EEU complience | 2022-2024 |
| Etoposide | L01CB | Podophyllotoxin Derivatives | Bringing dossier into the EEU complience | 2022-2024 |
| Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Bringing dossier into the EEU complience | 2022-2024 |
| Amlodipinum + Indapamidum + Perindoprilum | C09BX | Ингибиторы АПФ, другие комбинации | Marketing Authorization | 2022-2024 |
| Telmisartan + Amlodipin | C09DB | Angiotensin II receptor blockers (ARBs) and calcium channel blockers | Marketing Authorization | 2022-2024 |
| Аmorolfine | D01AE | ;Other Antifungals for topical use | Marketing Authorization | 2022-2024 |
| Apixaban | B01AF | Other Antithrombotic Agents | Marketing Authorization | 2022-2024 |
| Valaciclovir | J05AB | Nucleosides and nucleotides | Marketing Authorization | 2022-2024 |
| Gadopentetic acid | V08CA | Paramagnetic Contrast Media | Marketing Authorization | 2022-2024 |
| Geparin sodium | C05BA | Preparations With Heparin for topical use | Marketing Authorization | 2022-2024 |
| Dimetindene + Phenylephrine | R01AB | Sympathomimetics,Combinations Excl Corticosteroids | Marketing Authorization | 2022-2024 |
| Indapamid + Perindopril + Rosuvastatin | C10BX | HMG CoA reductase inhibitors, other combinations | Marketing Authorization | 2022-2024 |
| Pazufloxacin | J01MA | Fluoroquinolones | Marketing Authorization | 2022-2024 |
| Coffeinum + Paracetamolum + Phenylephrinum + Chlorphenaminum | N02BE | ;Anilides | Marketing Authorization | 2022-2024 |
| Paricalcitol | H05BX | Other anti-parathyroid agents | Marketing Authorization | 2022-2024 |
| Raltegravir | J05AX | Other Drugs For Treatment Of Tuberculosis | Marketing Authorization | 2022-2024 |
| Teicoplanin | J01XA | Glycopeptide Antibacterials | Marketing Authorization | 2022-2024 |
| Ursodeoxycholic acid | A05AA | Bile Acid Preparations | Marketing Authorization | 2022-2024 |
| Cefaktiv | J01DE | Fourth-generation cephalosporins | Marketing Authorization | 2022-2024 |
| Cefodizimum | J01DD | Third-generation cephalosporins | Marketing Authorization | 2022-2024 |
| Ceftriaxone + Sulbactam | J01DD | Third-generation cephalosporins | Marketing Authorization | 2022-2024 |
| Cefuroxime | J01RA | Combinations Of Antibacterials | Marketing Authorization | 2022-2024 |
| Hydrochlorothiazidum + Telmisartan | C09DA | Angiotensin II Antagonists and Diuretics | Bioequivalence CT | 2022-2024 |
| Amlodipinum + Perindoprilum + Rosuvastatinum | C10BX | HMG CoA reductase inhibitors, other combinations | Bioequivalence CT | 2022-2024 |
| Amlodipinum + Indapamidum + Perindoprilum | C09BX | Ингибиторы АПФ, другие комбинации | Bioequivalence CT | 2022-2024 |
| Diacerein | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | Bioequivalence CT | 2022-2024 |
| Diosmin + Hesperidin | C05CA | Bioflavonoids | Bioequivalence CT | 2022-2024 |
| Nimesulide | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | Bioequivalence CT | 2022-2024 |
| Anastrozole | L02BG | Enzyme Inhibitors | Bioequivalence CT | 2022-2024 |
| Axitinib | L01EK | Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors | Bioequivalence CT | 2022-2024 |
| Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Bioequivalence CT | 2022-2024 |
| Dolutegravir + Rilpivirine | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | 2022-2024 |
| Abemaciclibum | L01EF | Cyclin-dependent kinase (CDK) inhibitors | Bioequivalence CT | 2022-2024 |
| Glecaprevir + Pilbrentasvir | J05AX | Other Antivirals | Bioequivalence CT | 2022-2024 |
| Grazoprevir + Elbasvir | J05AP | Antivirals for treatment of HCV infections | Bioequivalence CT | 2022-2024 |
| Safinamid | N04BD | N04BD | User testing of leaflet | 2022-2024 |
| Drotaverine | A03AD | Papaverine and Derivatives | User testing of leaflet | 2022-2024 |
| Atorvastatin | C10AA | HMG CoA Reductase Inhibitors | User testing of leaflet | 2022-2024 |
| Benzoyl peroxide + Сlindamycin | D10AF | Antiinfectives For Treatment Of Acne | User testing of leaflet | 2022-2024 |
| Drospirenone + Ethinylestradiol | G03AA | Progestogens and estrogens, fixed combinations | User testing of leaflet | 2022-2024 |
| Apixaban | B01AF | Other Antithrombotic Agents | User testing of leaflet | 2022-2024 |
| Ticagrelor | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | User testing of leaflet | 2022-2024 |
| Gadopentetic acid | V08CA | Paramagnetic Contrast Media | User testing of leaflet | 2022-2024 |
| Etoricoxib | M01AH | Coxibs | User testing of leaflet | 2022-2024 |
| Gemcitabin | L01BC | Pyrimidine Analogues | User testing of leaflet | 2022-2024 |
| Glucosamine + Ibuprofen + Chondroitin sulfate | M01AE | Propionic Acid Derivatives | Bioequivalence CT | 2022-2024 |
| Apixaban | B01AF | Other Antithrombotic Agents | Bioequivalence CT | 2022-2024 |
| Alfacalcidol + Calcium carbonate | A11CC | Vitamin D and analogues | Bringing dossier into the EEU complience | 2022-2024 |
| Ambrisentan | C02KX | Antihypertensives for pulmonary arterial hypertension | Bringing dossier into the EEU complience | 2022-2024 |
| Aminoacids for parenteral nutrition | B05BA | Solutions for parenteral nutrition | Bringing dossier into the EEU complience | 2022-2024 |
| Aminoacids for parenteral nutrition + Other medicines [Fat emulsions + Dextrose + Multimineral] | B05BA | Solutions for parenteral nutrition | Bringing dossier into the EEU complience | 2022-2024 |
| Amorolfine | D01AE | Other Antifungals For Topical Use | Bringing dossier into the EEU complience | 2022-2024 |
| Anagrelide | L01XX | Other antineoplastic agents | Bringing dossier into the EEU complience | 2022-2024 |
| Bromhexine + Guaifenesin + Salbutamol | R05C | EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS | Bringing dossier into the EEU complience | 2022-2024 |
| Varicella Zoster Vaccines | J07BK | Varicella Zoster Vaccines | Bringing dossier into the EEU complience | 2022-2024 |
| Measles, mumps, rubella, and varicella vaccine | J07BD | Measles Vaccines | Bringing dossier into the EEU complience | 2022-2024 |
| Papillomavirus vaccines | J07BM | Papillomavirus vaccines | Bringing dossier into the EEU complience | 2022-2024 |
| Water for injections | V07AB | Solvents and Diluting Agents,Incl Irrigat Solut | Bringing dossier into the EEU complience | 2022-2024 |
| Gemcitabine | L01BC | Pyrimidine analogues | Bringing dossier into the EEU complience | 2022-2024 |
| Glucoseminyl muramildipeptide | L03A | IMMUNOSTIMULANTS | Bringing dossier into the EEU complience | 2022-2024 |
| Granisetron | A04AA | Serotonin (5HT3) antagonists | Bringing dossier into the EEU complience | 2022-2024 |
| Dactinomycin | L01DA | Actinomycines | Bringing dossier into the EEU complience | 2022-2024 |
| Dexmedetomidine | N05CM | Other hypnotics and sedatives | Bringing dossier into the EEU complience | 2022-2024 |
| Dextromethorphan + Paracetamol + Phenylephrine + Chlorphenamine | N07XX | Anilides | Bringing dossier into the EEU complience | 2022-2024 |
| Decitabine | L01BC | Pyrimidine analogues | Bringing dossier into the EEU complience | 2022-2024 |
| Diclofenac + Orphenadrine | M01AB | Acetic acid derivatives and related substances | Bringing dossier into the EEU complience | 2022-2024 |
| Dinutuximab beta | L01FX | Other monoclonal antibodies | Bringing dossier into the EEU complience | 2022-2024 |
| Duloxetine | N06AX | Other antidepressants | Bringing dossier into the EEU complience | 2022-2024 |
| Fat Emulsions | B05BA | Solutions for parenteral nutrition | Bringing dossier into the EEU complience | 2022-2024 |
| Imipenem and cilastatin | J01DH | Carbapenems | Bringing dossier into the EEU complience | 2022-2024 |
| Imiquimod | D06BB | Antivirals | Bringing dossier into the EEU complience | 2022-2024 |
| Potassium acetate + Calcium acetate + Magnesium acetate + Sodium acetate + Sodium chloride | B05BB | Solutions affecting the electrolyte balance | Bringing dossier into the EEU complience | 2022-2024 |
| Carboplatin | L01XA | Platinum compounds | Bringing dossier into the EEU complience | 2022-2024 |
| Ketorolac | M01AB | Acetic acid derivatives and related substances | Bringing dossier into the EEU complience | 2022-2024 |
| Ketoanalogues of aminoacids | V06DD | Amino Acids,Incl Combinations With Polypeptides | Bringing dossier into the EEU complience | 2022-2024 |
| Caffeine + Paracetamol + Phenylephrine + Pheniramine | N02BE | Anilides | Bringing dossier into the EEU complience | 2022-2024 |
| Lactulose | A06AD | Osmotically acting laxatives | Bringing dossier into the EEU complience | 2022-2024 |
| Levofloxacin | J01MA | Fluoroquinolones | Bringing dossier into the EEU complience | 2022-2024 |
| Levocetirizine | R06AE | Piperazine derivatives | Bringing dossier into the EEU complience | 2022-2024 |
| Leflunomide | L04AA | Selective immunosuppressants | Bringing dossier into the EEU complience | 2022-2024 |
| Bacteriolysas | L03AX | Other Immunostimulants | Bringing dossier into the EEU complience | 2022-2024 |
| Meglumine acridonacetate | L03AX | Other Immunostimulating Agents | Bringing dossier into the EEU complience | 2022-2024 |
| Meropenem | J01DH | Carbapenems | Bringing dossier into the EEU complience | 2022-2024 |
| Mometasone | D07AC | Corticosteroids, potent (group III) | Bringing dossier into the EEU complience | 2022-2024 |
| Mometasone + Azelastine | R01A | DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE | Bringing dossier into the EEU complience | 2022-2024 |
| Nimesulide | M01AX | Other antiinflammatory and antirheumatic agents, non-steroids | Bringing dossier into the EEU complience | 2022-2024 |
| Oxaliplatin | L01XA | Platinum compounds | Bringing dossier into the EEU complience | 2022-2024 |
| Omeprazole | A02BC | Proton pump inhibitors | Bringing dossier into the EEU complience | 2022-2024 |
| Paclitaxel | L01CD | Taxanes | Bringing dossier into the EEU complience | 2022-2024 |
| Piperacillin + Tazobactam | J01CR | Combinations of penicillins, incl. beta-lactamase inhibitors | Bringing dossier into the EEU complience | 2022-2024 |
| Multivitamins [parenteral injection] | A11BA | Multivitamins, plain | Bringing dossier into the EEU complience | 2022-2024 |
| Polymyxin B | A07AA | Antibiotics | Bringing dossier into the EEU complience | 2022-2024 |
| Peritoneal Dialytics | B05D | Peritoneal Dialytics | Bringing dossier into the EEU complience | 2022-2024 |
| Rocuronium bromide | M03AC | Other quaternary ammonium compounds | Bringing dossier into the EEU complience | 2022-2024 |
| Simoctocog alfa | B02BD | Blood Coagulation Factors | Bringing dossier into the EEU complience | 2022-2024 |
| Natural peptides and cytokines peptide-protein complex | L03 | Immunomodulating Agents | Bringing dossier into the EEU complience | 2022-2024 |
| Suprima-Broncho | R05X | OTHER COLD PREPARATIONS | Bringing dossier into the EEU complience | 2022-2024 |
| Temozolomide | L01AX | Other alkylating agents | Bringing dossier into the EEU complience | 2022-2024 |
| Tizanidine | M03BX | Other centrally acting agents | Bringing dossier into the EEU complience | 2022-2024 |
| Coagulation Factor IX | B02BD | Blood Coagulation Factors | Bringing dossier into the EEU complience | 2022-2024 |
| Furazidin | J01XE | Nitrofuran derivatives | Bringing dossier into the EEU complience | 2022-2024 |
| Celecoxib | L01XX | Other antineoplastic agents | Bringing dossier into the EEU complience | 2022-2024 |
| Cefoperazone+Sulbactam | J01DD | Third-generation cephalosporins | Bringing dossier into the EEU complience | 2022-2024 |
| Ceftriaxone | J01DD | Third-generation cephalosporins | Bringing dossier into the EEU complience | 2022-2024 |
| Cefuroxime | J01DC | Second-generation cephalosporins | Bringing dossier into the EEU complience | 2022-2024 |
| Ciclosporin | L04AD | Calcineurin inhibitors | Bringing dossier into the EEU complience | 2022-2024 |
| Cytisine | N07BA | Drugs used in nicotine dependence | Bringing dossier into the EEU complience | 2022-2024 |
| Etoposide | L01CB | Podophyllotoxin derivatives | Bringing dossier into the EEU complience | 2022-2024 |
| Patiromer | V03AE | Drugs For Treatment Of Hyperkalemia And Hyperphosphatemia | User testing of leaflet | 2022-2024 |
| Rosuvastatin | C10AA | HMG CoA reductase inhibitors | User testing of leaflet | 2022-2024 |
| Hydrochlorothiazide + losartan | C09DA | Angiotensin II Antagonists And Diuretics | User testing of leaflet | 2022-2024 |
| Polatuzumab vedotin | B01AC | Platelet Aggregation Inhibitors Excl. Heparin | User testing of leaflet | 2022-2024 |
| Tranexamic acid | B02AA | Аминокислоты | User testing of leaflet | 2022-2024 |
| Insulin glargine | A10AE | Insulins And Analogues For Injection, Long-Acting | User testing of leaflet | 2022-2024 |
| Anifrolumab | L04AA | Selective Immunosuppressants | User testing of leaflet | 2022-2024 |
| Perindopril | C09AA | ACE Inhibitors, Plain | User testing of leaflet | 2022-2024 |
| Ipratropium bromide + xylometazoline | R01AB | Sympathomimetics, combinations excl. Corticosteroids | User testing of leaflet | 2022-2024 |
| Rivaroxaban | B01AF01 | Direct factor Xa inhibitors | User testing of leaflet | 2022-2024 |
| Levonorgestrel | G02BA | Intrauterine Contraceptives | User testing of leaflet | 2022-2024 |
| Amlodipine + perindopril | C09BB | ACE Inhibitors And Calcium Channel Blockers | User testing of leaflet | 2022-2024 |
| Mometasone | R01AD | Corticosteroids | User testing of leaflet | 2022-2024 |
| Dabigatran etexilate | B01AE | Direct Thrombin Inhibitors | User testing of leaflet | 2022-2024 |
| Adapalene | D10AD | Retinoids for topical use in acne | User testing of leaflet | 2022-2024 |
| Ademetionine | A16AA | Amino acids and derivatives | User testing of leaflet | 2022-2024 |
| Acalabrutinib | L01EL | Bruton`s tyrosine kinase (BTK) inhibitors | User testing of leaflet | 2022-2024 |
| Ambroxol | R05CB | Mucolytics | User testing of leaflet | 2022-2024 |
| Amiodarone | C01BD | Antiarrhythmics, Class III | User testing of leaflet | 2022-2024 |
| Valsartan, Amlodipine and Hydrochlorothiazide | C09DX | Angiotensin II antagonists, other combinations | User testing of leaflet | 2022-2024 |
| Amlodipinum + Indapamidum + Perindoprili | C09BX | ACE inhibitors, other combinations | User testing of leaflet | 2022-2024 |
| Telmisartan and Amlodipine | C09DB | Angiotensin II antagonists and calcium channel blockers | User testing of leaflet | 2022-2024 |
| Amoxicillin+Clavulanic acid | J01CR | Amoxicillin and Enzyme Inhibitor | User testing of leaflet | 2022-2024 |
| Amorolfine | D01AE | Other Antifungals for topical use | User testing of leaflet | 2022-2024 |
| Asfotase alfa | A16AB | Enzymes | User testing of leaflet | 2022-2024 |
| Atezolizumab | L01FF | PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors | User testing of leaflet | 2022-2024 |
| Atorvastatin | C10AA | HMG CoA reductase inhibitors | User testing of leaflet | 2022-2024 |
| Aceclofenac | M01AB | Acetic Acid Derivatives And Related Substances | User testing of leaflet | 2022-2024 |
| Belimumab | L04AA | Selective Immunosuppressive Agents | User testing of leaflet | 2022-2024 |
| Busulfan | L01AB | Alkyl sulfonates | User testing of leaflet | 2022-2024 |
| Bacterial and Viral Vaccines, Combined | J07CA | Bacterial and Viral Vaccines, Combined | User testing of leaflet | 2022-2024 |
| Valsartan | C09CA | Angiotensin II antagonists, plain | User testing of leaflet | 2022-2024 |
| Valsartan+Hydrochlorothiazide | C09DX | Valsartan and diuretics | User testing of leaflet | 2022-2024 |
| Valproic Acid | N03AG | Fatty acid derivatives | User testing of leaflet | 2022-2024 |
| Vancomycin | J01XA | Glycopeptide antibacterials | User testing of leaflet | 2022-2024 |
| Vilanterol, umeclidinium bromide and fluticasone furoate | R03AL | Adrenergics in combination with anticholinergics | User testing of leaflet | 2022-2024 |
| Vildagliptin | A10BH | Dipeptidyl peptidase 4 (DPP-4) inhibitors | User testing of leaflet | 2022-2024 |
| Metformin and vildagliptin | A10BD | Combinations Of Oral Blood Glucose Lowering Drugs | User testing of leaflet | 2022-2024 |
| Gadopentetic acid | V08CA | Paramagnetic Contrast Media | User testing of leaflet | 2022-2024 |
| Gemcitabine | L01BC | Pyrimidine analogues | User testing of leaflet | 2022-2024 |
| Gestodene and Estrogen | G03AA | Progestogens and estrogens, fixed combinations | User testing of leaflet | 2022-2024 |
| Dabigatran etexilate | B01AE | Direct thrombin inhibitors | User testing of leaflet | 2022-2024 |
| Danicopan | L04AJ | Selective Immunosuppressive Agents | User testing of leaflet | 2022-2024 |
| Dapagliflozin | A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | User testing of leaflet | 2022-2024 |
| ;Dexpanthenol | D03AX | Other cicatrizants | User testing of leaflet | 2022-2024 |
| Dienogest + Ethinylestradiol | G03AA | Progestogens and estrogens, fixed combinations | User testing of leaflet | 2022-2024 |
| Dimenhydrinate | R06AA | Aminoalkyl ethers | User testing of leaflet | 2022-2024 |
| Dolutegravir and rilpivirin | J05AR | Antivirals for treatment of HIV infections, combinations | User testing of leaflet | 2022-2024 |
| Drospirenone + Ethinylestradiol | G03AA | Progestogens and estrogens, fixed combinations | User testing of leaflet | 2022-2024 |
| Ibuprofen, Combinations | M01AE | Propionic acid derivatives | User testing of leaflet | 2022-2024 |
| Ivacaftor, tezacaftor and elexacaftor | R07AX | Other respiratory system products | User testing of leaflet | 2022-2024 |
| Rosuvastatin, perindopril and indapamide | C10BX | HMG CoA reductase inhibitors, other combinations | User testing of leaflet | 2022-2024 |
| Insulin glargine | A10AE | Insulins and analogues for injection, long-acting | User testing of leaflet | 2022-2024 |
| Insulin glulisine | A10AB | Insulins and analogues for injection, fast-acting | User testing of leaflet | 2022-2024 |
| Iohexol | V08AB | Watersoluble, nephrotropic, low osmolar X-ray contrast media | User testing of leaflet | 2022-2024 |
| Cabazitaxel | L01CD | Taxanes | User testing of leaflet | 2022-2024 |
| Capivasertib | L01EX | Other protein kinase inhibitors | User testing of leaflet | 2022-2024 |
| Carboplatin | L01XA | Platinum compounds | User testing of leaflet | 2022-2024 |
| Carfilzomib | L01XG | Proteasome inhibitors | User testing of leaflet | 2022-2024 |
| Caspofungin | J02AX | Other antimycotics for systemic use | User testing of leaflet | 2022-2024 |
| Clindamycin | D10AF | Antiinfectives for treatment of acne | User testing of leaflet | 2022-2024 |
| Colistimethate sodium | J01XB | Polymyxins | User testing of leaflet | 2022-2024 |
| Xylometazoline | R01AA | Sympathomimetics, plain | User testing of leaflet | 2022-2024 |
| Lansoprazole | A02BC | Proton pump inhibitors | User testing of leaflet | 2022-2024 |
| Latanoprost | S01EE | Prostaglandin Analogues | User testing of leaflet | 2022-2024 |
| Levonorgestrel | G03AC | Progestogens | User testing of leaflet | 2022-2024 |
| Levofloxacin | J01MA | Fluoroquinolones | User testing of leaflet | 2022-2024 |
| Metoprolol | C07AB | Beta blocking agents, selective | User testing of leaflet | 2022-2024 |
| Metronidazole | D06BX | Other chemotherapeutics | User testing of leaflet | 2022-2024 |
| Moxifloxacin | J01MA | Fluoroquinolones | User testing of leaflet | 2022-2024 |
| Mosunetuzumab | L01FX | Other monoclonal antibodies | User testing of leaflet | 2022-2024 |
| Norelgestromin + ethinylestradiol | G03AA | Progestogens and estrogens, fixed combinations | User testing of leaflet | 2022-2024 |
| Ocrelizumab | L04AA | Selective immunosuppressants | User testing of leaflet | 2022-2024 |
| Olaparib | L01XK | Poly (ADP-ribose) polymerase (PARP) inhibitors | User testing of leaflet | 2022-2024 |
| Pazufloxacin | J01MA | Fluoroquinolones | User testing of leaflet | 2022-2024 |
| Pantoprazole | A02BC | Proton pump inhibitors | User testing of leaflet | 2022-2024 |
| Perampanel | N03AX | Other antiepileptics | User testing of leaflet | 2022-2024 |
| Pertuzumab | L01FD | HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors | User testing of leaflet | 2022-2024 |
| Pertuzumab and trastuzumab | L01XY | Combinations of antineoplastic agents | User testing of leaflet | 2022-2024 |
| Piperacillin + Tazobactam | J01CR | Combinations of penicillins, incl. beta-lactamase inhibitors | User testing of leaflet | 2022-2024 |
| Hederae folium | R05CA | Expectorants | User testing of leaflet | 2022-2024 |
| Multivitamins, Plain | A11BA | Multivitamins, Plain | User testing of leaflet | 2022-2024 |
| Ravulizumab | L04AA | Selective immunosuppressants | User testing of leaflet | 2022-2024 |
| Rivaroxaban | B01AF | Direct factor Xa inhibitors | User testing of leaflet | 2022-2024 |
| Rituximab | L01FA | CD20 (Clusters of Differentiation 20) inhibitors | User testing of leaflet | 2022-2024 |
| Sevoflurane | N01AB | Halogenated hydrocarbons | User testing of leaflet | 2022-2024 |
| Selumetinib | L01EE | Mitogen-activated protein kinase (MEK) inhibitors | User testing of leaflet | 2022-2024 |
| Sulbactam | J01CG | Beta-lactamase inhibitors | User testing of leaflet | 2022-2024 |
| Tezepelumab | R03DX | Other systemic drugs for obstructive airway diseases | User testing of leaflet | 2022-2024 |
| Telmisartan | C09CA | Angiotensin II antagonists, plain | User testing of leaflet | 2022-2024 |
| Testosterone | G03BA | 3-Oxoandrosten (4) Derivatives | User testing of leaflet | 2022-2024 |
| Tetryzoline | S01GA | Sympathomimetics Used As Decongestants | User testing of leaflet | 2022-2024 |
| Ticagrelor | B01AC | Platelet aggregation inhibitors excl. Heparin | User testing of leaflet | 2022-2024 |
| Trabectedin | L01CX | Other plant alkaloids and natural products | User testing of leaflet | 2022-2024 |
| Trastuzumab | L01FD | HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors | User testing of leaflet | 2022-2024 |
| Trastuzumab deruxtecan | L01FD | HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors | User testing of leaflet | 2022-2024 |
| Tremelimumab | L01FX | Other monoclonal antibodies | User testing of leaflet | 2022-2024 |
| Fostemsavir | J05AX | Other antivirals | User testing of leaflet | 2022-2024 |
| Cetirizine | S01GX | Other Antiallergics | User testing of leaflet | 2022-2024 |
| Cefepime + sulbactam | J01DE | Fourth-generation cephalosporins | User testing of leaflet | 2022-2024 |
| Ceftriaxone + Sulbactam | J01DD | Third-generation cephalosporins | User testing of leaflet | 2022-2024 |
| Cefuroxime | J01DC | Second-generation cephalosporins | User testing of leaflet | 2022-2024 |
| Emicizumab | B02BX | Other systemic hemostatics | User testing of leaflet | 2022-2024 |
| Enalapril | C09AA | ACE inhibitors, plain | User testing of leaflet | 2022-2024 |
| Ertapenem | J01DH | Carbapenems | User testing of leaflet | 2022-2024 |
| Isotretinoin | D10BA | Retinoids for treatment of acne | User testing of leaflet | 2022-2024 |
| Metformin + glimepiride | A10BD | Combinations Of Oral Blood Glucose Lowering Drugs | User testing of leaflet | 2022-2024 |
| Amino Acids | B05BA | Solutions for parenteral nutrition | User testing of leaflet | 2022-2024 |
| Hydrochlorothiazide + ramipril | C09BA | ACE inhibitors and diuretics | User testing of leaflet | 2022-2024 |
| Apixaban | B01AF | Direct factor Xa inhibitors | User testing of leaflet | 2022-2024 |
| Acetylsalicylic acid | B01AC | Platelet aggregation inhibitors excl. Heparin | User testing of leaflet | 2022-2024 |
| Metamizole sodium | N02BB | Pyrazolones | User testing of leaflet | 2022-2024 |
| Ginkgo biloba | N06DX | Other anti-dementia drugs | User testing of leaflet | 2022-2024 |
| Hyoscine butylbromide | A03BB | Belladonna alkaloids, semisynthetic, quaternary ammonium compounds | User testing of leaflet | 2022-2024 |
| Agomelatin | N06AX | Other antidepressants | User testing of leaflet | 2022-2024 |
| Valsartan + indapamide | C09DA | Angiotensin II antagonists and diuretics | User testing of leaflet | 2022-2024 |
| Varicella vaccine (live)) | J07BK | Zoster, live attenuated | User testing of leaflet | 2022-2024 |
| Salbutamol | R03AC | Selective beta-2-adrenoreceptor agonists | User testing of leaflet | 2022-2024 |
| Water for injections | V07AB | Solvents and Diluting Agents,Incl Irrigat Solut | User testing of leaflet | 2022-2024 |
| Gadobutrol | V08CA | Paramagnetic contrast media | User testing of leaflet | 2022-2024 |
| Obinutuzumab | L01FA | CD20 (Clusters of Differentiation 20) inhibitors | User testing of leaflet | 2022-2024 |
| Granisetron | A04AA | Serotonin (5HT3) antagonists | User testing of leaflet | 2022-2024 |
| Dexketoprofen | M01AE | Propionic acid derivatives | User testing of leaflet | 2022-2024 |
| Cyproterone + ethinylestradiol | G03HB | Antiandrogens and estrogens | User testing of leaflet | 2022-2024 |
| Cefodizime | J01DD | Third-Generation Cephalosporins | User testing of leaflet | 2022-2024 |
| Alanyl glutamine | B05XB | Amino acids | User testing of leaflet | 2022-2024 |
| Goserelin | L02AE | Gonadotropin releasing hormone analogues | User testing of leaflet | 2022-2024 |
| Rabeprazole | A02BC | Proton pump inhibitors | User testing of leaflet | 2022-2024 |
| Sebelipase alfa | A16AB | Enzymes | User testing of leaflet | 2022-2024 |
| Lamivudine + abacavir | J05AR | Antivirals for treatment of HIV infections, combinations | User testing of leaflet | 2022-2024 |
| Acetylsalicylic acid + clopidogrel | B01AC | Platelet aggregation inhibitors excl. Heparin | User testing of leaflet | 2022-2024 |
| Lamotrigine | N03AX | Other antiepileptics | User testing of leaflet | 2022-2024 |
| Levosalbutamol | R03AC | Selective Beta-2-Adrenoceptor Agonists | User testing of leaflet | 2022-2024 |
| Glucosaminylmuramyldipeptide | L03A | Immunostimulating Agents | User testing of leaflet | 2022-2024 |
| Losartan | C09CA | Angiotensin II antagonists, plain | User testing of leaflet | 2022-2024 |
| Лорноксикам | M01AC | Oxicams | User testing of leaflet | 2022-2024 |
| Pyridoxine + magnesium lactate | A12CC | Magnesium | User testing of leaflet | 2022-2024 |
| Naproxen | M01AE | Propionic acid derivatives | User testing of leaflet | 2022-2024 |
| Ibuprofen | M01AE | Propionic acid derivatives | User testing of leaflet | 2022-2024 |
| Indapamide + perindopril | C09BA | ACE inhibitors and diuretics | User testing of leaflet | 2022-2024 |
| Simoctocog alfa | B02BD | Blood coagulation factors | User testing of leaflet | 2022-2024 |
| Benzydamine | A01AD | Other agents for local oral treatment | User testing of leaflet | 2022-2024 |
| Paroxetine | N06AB | Selective serotonin reuptake inhibitors | User testing of leaflet | 2022-2024 |
| Paracetamol | N02BE | Anilides | User testing of leaflet | 2022-2024 |
| Diphtheria and tetanus adsorbed, pertussis, poliomyelitis and Haemophilus influenzae type b vaccine) | J07CA | Bacterial and viral vaccines, combined | User testing of leaflet | 2022-2024 |
| Amlodipine + perindopril | C09BB | ACE inhibitors and calcium channel blockers | User testing of leaflet | 2022-2024 |
| Gadoxetic acid | V08CA | Paramagnetic contrast media | User testing of leaflet | 2022-2024 |
| Measles, mumps, rubella, and varicella vaccine | J07BD | Measles vaccines | User testing of leaflet | 2022-2024 |
| Propofol | N01AX | Other general anesthetics | User testing of leaflet | 2022-2024 |
| Budesonide | R03BA | Glucocorticoids | User testing of leaflet | 2022-2024 |
| Nifuroxazide | A07AX | Other intestinal antiinfectives | User testing of leaflet | 2022-2024 |
| Albumin | B05AA | Blood Substitutes And Plasma Protein Fractions | User testing of leaflet | 2022-2024 |
| Zanamivir | J05AH | Neuraminidase inhibitors | User testing of leaflet | 2022-2024 |
| Zidovudine | J05AF | Nucleoside and nucleotide reverse transcriptase inhibitors | User testing of leaflet | 2022-2024 |
| Amlodipine + perindopril + rosuvastatin | C10BX | HMG CoA reductase inhibitors, other combinations | User testing of leaflet | 2022-2024 |
| Rocuronium Bromide | M03AC | Other quaternary ammonium compounds | User testing of leaflet | 2022-2024 |
| Metformin + dapagliflozin | A10BD | Combinations of oral blood glucose lowering drugs | User testing of leaflet | 2022-2024 |
| Palivizumab | J06BD | Antiviral monoclonal antibodies | User testing of leaflet | 2022-2024 |
| Sulfasalazine | A07EC | Aminosalicylic acid and similar agents | User testing of leaflet | 2022-2024 |
| Telmisartan + indapamide | C09DA | Angiotensin II antagonists and diuretics | User testing of leaflet | 2022-2024 |
| hydrochlorothiazide + telmisartan + amlodipine | C09DX | Angiotensin II antagonists, other combinations | User testing of leaflet | 2022-2024 |
| Dolutegravir | J05AJ | Integrase inhibitors | User testing of leaflet | 2022-2024 |
| Omeprazole | A02BC | Proton pump inhibitors | User testing of leaflet | 2022-2024 |
| Iopromide | V08AB | Watersoluble, nephrotropic, low osmolar X-ray contrast media | User testing of leaflet | 2022-2024 |
| Finerenone | C03DA | Aldosterone antagonists | User testing of leaflet | 2022-2024 |
| Etoposide | L01CB | Podophyllotoxin derivatives | User testing of leaflet | 2022-2024 |
| Hepatitis A vaccine | J07BC | Hepatitis vaccines | User testing of leaflet | 2022-2024 |
| Eribulin | L01XX | Other antineoplastic agents | User testing of leaflet | 2022-2024 |
| Maraviroc | J05AX | Other antivirals | User testing of leaflet | 2022-2024 |
| Aflibercept | S01LA | Antineovascularisation agents | User testing of leaflet | 2022-2024 |
| Esomeprazol | A02BC | Proton pump inhibitors | User testing of leaflet | 2022-2024 |
| ;Hydrochlorothiazide + enalapril | C09BA | ACE inhibitors and diuretics | User testing of leaflet | 2022-2024 |
| Lamivudine | J05AF | Nucleoside and nucleotide reverse transcriptase inhibitors | User testing of leaflet | 2022-2024 |
| Acetylcysteine | R05CB | Mucolytics | User testing of leaflet | 2022-2024 |
| Ethinylestradiol + drospirenone + levomefolate calcium | G03AA | Progestogens and estrogens, fixed combinations | User testing of leaflet | 2022-2024 |
| Cetirizine | R06AE | Piperazine Derivatives | User testing of leaflet | 2022-2024 |
| Amlodipine | C08CA | Dihydropyridine Derivatives | Рharmacovigilance | Present |
| Atracurium besylate | M03AC | Other Quaternary Ammonium Compounds | Рharmacovigilance | Present |
| Carbamazepine | N03AF | Carboxamide Derivatives | Рharmacovigilance | Present |
| Celecoxib | M01AH | Coxibs | Рharmacovigilance | Present |
| Cisplatin | L01XA | Platinum Compounds | Рharmacovigilance | Present |
| Docetaxel | L01CD | Taxanes | Рharmacovigilance | Present |
| Efavirenz | J05AG | Non-nucleoside reverse transcriptase inhibitors | Рharmacovigilance | Present |
| Epirubicin | L01DB | Anthracyclines and Related Substances | Рharmacovigilance | Present |
| Ferric (III) hydroxide sacharose complex | B03AC | Iron, Parenteral Preparations | Рharmacovigilance | Present |
| Gemcitabine | L01BC | Pyrimidine Analogues | Рharmacovigilance | Present |
| Imipenem + Cilastatin | J01DH | Carbapenems | Рharmacovigilance | Present |
| Isoniazid | J04AC | Hydrazides | Рharmacovigilance | Present |
| Loratadine | R06AX | Other Antihistamines for systemic use | Рharmacovigilance | Present |
| Moxifloxacin | J01MA | Fluoroquinolones | Рharmacovigilance | Present |
| Ornidazole | J01XD | Imidazole Derivatives | Рharmacovigilance | Present |
| Paracetamol | N02B | Other Analgesics and Antipyretics | Рharmacovigilance | Present |
| Pregabalin | N03AX | Other Antiepileptics | Рharmacovigilance | Present |
| Pyrazinamide | J04AK | Other Drugs For Treatment Of Tuberculosis | Рharmacovigilance | Present |
| Temozolomide | L01AX | Other Alkylating Agents | Рharmacovigilance | Present |
| Ciprofloxacin | J01MA | Fluoroquinolones | Рharmacovigilance | Present |
| Metronidazole | J01XD | Imidazole Derivatives | Рharmacovigilance | Present |
| Diclofenac | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | Рharmacovigilance | Present |
| Ivabradine | C01EB | Other Cardiac Preparations | Рharmacovigilance | Present |
| Famciclovir | J05AB | Nucleosides and nucleotides | Рharmacovigilance | Present |
| Indocyanine green | V04CX | Other Diagnostic Agents | Рharmacovigilance | Present |
| Sulodexide | B01AB | Heparin Group | Рharmacovigilance | Present |
| Anagrelide | L01XX | Other Antineoplastic Agents | Рharmacovigilance | Present |
| Hyoscine butylbromide | A03BB | Belladonna Alkaloids Semisynt,Quater Ammonium Comp | Рharmacovigilance | Present |
| Fluvoxamine | N06AB | Serotonin Reuptake Inhibitors Selective | Рharmacovigilance | Present |
| Cytisine | N07BA | Antismoking Agents | Рharmacovigilance | Present |
| Natamycin | A07AA | Antibiotics | Рharmacovigilance | Present |
| Paracetamol + Phenylephrine + Pheniramine + Ascorbic acid | N02B | Other Analgesics and Antipyretics | Рharmacovigilance | Present |
| Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Streptococcus pneumoniae | L03AX | Other Immunostimulating Agents | Рharmacovigilance | Present |
| Acetylcysteine | R05CB | Mucolytics | Рharmacovigilance | Present |
| Ascorbic acid | A11GA | Ascorbic Acid, Plain | Рharmacovigilance | Present |
| Nitisinone | A16AX | Various Alimentary Tract and Metabolism Products | Рharmacovigilance | Present |
| Phosphazide | J05AF | Nucleoside reverse transcriptase inhibitors | Рharmacovigilance | Present |
| Meglumine acridonacetate | L03AX | Other Immunostimulating Agents | Рharmacovigilance | Present |
| Cinacalcet | H05BX | Other anti-parathyroid agents | Рharmacovigilance | Present |
| Dexmedetomidine | N05CM | Other Hypnotics and Sedatives | Рharmacovigilance | Present |
| Tigecycline | J01AA | Tetracyclines | Рharmacovigilance | Present |
| Teriflunomide | L04AA | Selective Immunosuppressive Agents | Рharmacovigilance | Present |
| Iodixanol | V08A | X-Ray Contrast Media, Iodinated | Рharmacovigilance | Present |
| Paricalcitol | H05BX | Other anti-parathyroid agents | Рharmacovigilance | Present |
| Gadopentetic acid | V08CA | Paramagnetic Contrast Media | Рharmacovigilance | Present |
| Gadodiamide | V08CA | Paramagnetic Contrast Media | Рharmacovigilance | Present |
| Dantrolene | M03CA | Dantrolene and Derivatives | Рharmacovigilance | Present |
| Dapagliflozin | A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | Рharmacovigilance | Present |
| Raltegravir | J05AX | Other Drugs For Treatment Of Tuberculosis | Рharmacovigilance | Present |
| Etravirin | J05AG | Ненуклеозиды - ингибиторы обратной транскриптазы | Рharmacovigilance | Present |
| Clofaziminum | J04BA | Drugs For Treatment Of Lepra | Рharmacovigilance | Present |
| Apixaban | B01AF | Other Antithrombotic Agents | Рharmacovigilance | Present |
| Rivaroxaban | B01AF | Direct factor Xa inhibitors | Рharmacovigilance | Present |
| Eribulin | L01XX | Other Antineoplastic Agents | Рharmacovigilance | Present |
| Cabazitaxel | L01CD | Taxanes | Рharmacovigilance | Present |
| Eltrombopag | B02BX | Other systemic hemostatics | Рharmacovigilance | Present |
| Dabigatrani etexilas | B01AA | Vitamin K Antagonists | Рharmacovigilance | Present |
| Cefoperazone + Sulbactam | J01DD | Third-generation cephalosporins | Рharmacovigilance | Present |
| Meropenem | J01DH | Carbapenems | Рharmacovigilance | Present |
| Ampicillin + Sulbactam | J01CR | Comb Of Penicillins, Incl. Beta-Lactamase Inhib. | Рharmacovigilance | Present |
| Amoxicillin + Sulbactam | J01CG | Beta-Lactamase Inhibitors | Рharmacovigilance | Present |
| Ceftriaxone + Sulbactam | J01DD | Third-generation cephalosporins | Рharmacovigilance | Present |
| Cefuroxime | J01RA | Combinations Of Antibacterials | Рharmacovigilance | Present |
| Piperacillin + Tazobactam | J01CR | Piperacillin and Enzyme Inhibitor | Рharmacovigilance | Present |
| Biapenem | J01DD | Third-generation cephalosporins | Рharmacovigilance | Present |
| Sulbactam | J01DD | Third-generation cephalosporins | Рharmacovigilance | Present |
| Diacerein | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | Рharmacovigilance | Present |
| Polymyxin B | J01XB | Polymyxins | Рharmacovigilance | Present |
| Ornidazole + Ciprofloxacin | J01RA | Combinations Of Antibacterials | Рharmacovigilance | Present |
| Alfacalcidol | A11CC | Vitamin D and Analogues | Рharmacovigilance | Present |
| Glucosamine + Chondroitin sulfate Potassium Adipate + Vitamin E | M09AX | Other Drugs For Disord. Of The Musc.-Skeletal Syst | Рharmacovigilance | Present |
| Nimesulide | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | Рharmacovigilance | Present |
| Сiclosporin | L04AD | Calcineurin inhibitors | Рharmacovigilance | Present |
| Dextromethorphanum+ Paracetamolum + Phenylephrinum+ Chlorphenaminum | N02BE | ;Anilides | Рharmacovigilance | Present |
| Cycloserine | J04A | Drugs For Treatment Of Tuberculosis | Рharmacovigilance | Present |
| Mycophenolate mofetil | L04AA | Selective Immunosuppressive Agents | Рharmacovigilance | Present |
| Lactulose | A06AX | Other Laxatives | Рharmacovigilance | Present |
| Ketorolac | M01A | Antiinflammatory/Antirheumatic Prod.,Non-Steroids | Рharmacovigilance | Present |
| Levofloxacin | J01MA | Fluoroquinolones | Рharmacovigilance | Present |
| Tizanidine | M03BX | Other Centrally Acting Agents | Рharmacovigilance | Present |
| Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Рharmacovigilance | Present |
| Aminosalicylic acid | J04AA | Aminosalicylic Acid and Derivatives | Рharmacovigilance | Present |
| Acetylsalicylic acid+Ascorbic acid | N02BA | Salicylic Acid and Derivatives | Рharmacovigilance | Present |
| Micafungin | J02AX | Other Antimycotics for systemic use | Рharmacovigilance | Present |
| Fondaparinux sodium | B01AX | ;Other Antithrombotic Agents | Рharmacovigilance | Present |
| Cefepime + Sulbactam | J01DE | Fourth-generation cephalosporins | Рharmacovigilance | Present |
| Dimetinden | R06A | Antihistamines for systemic use | Рharmacovigilance | Present |
| Fluconazole | J02AC | Triazole Derivatives | Рharmacovigilance | Present |
| Combined herb drug | A01AD | Other Agents For Local Oral Treatment | Phase III CT | Present |
| Levocetirizine | R06AE | Piperazine Derivatives | Рharmacovigilance | Present |
| Alverine + Simeticone | A03AX | Other Synthetic Anticholinergic Agents | Bioequivalence CT | Present |
| Tibolone | G03CX | Other estrogens | Marketing Authorization | Present |
| Ertapenem | J01DH | Carbapenems | Marketing Authorization | Present |
| Ceftriaxone + Sulbactam | J01DD | Third-generation cephalosporins | Marketing Authorization | Present |
| Erlotinib | L01XE | Protein kinase inhibitors | Marketing Authorization | Present |
| Paliperidone | N05AX | ;Other Antipsychotics | Marketing Authorization | Present |
| Piperacillin + Tazobactam | J01CR | Piperacillin and Enzyme Inhibitor | Marketing Authorization | Present |
| Sulbactam | J01DD | Third-generation cephalosporins | Marketing Authorization | Present |
| Lansoprazole | A02BD | Other Drugs For Treatment Of Peptic Ulcer | Marketing Authorization | Present |
| Fat Emulsions For Parenteral Nutrition | B05BA | Solutions For Parenteral Nutrition | Marketing Authorization | Present |
| Vancomycin | J01XA | Glycopeptide Antibacterials | Marketing Authorization | Present |
| Salbutamol | R03AC | Selective beta-2-adrenoreceptor agonists | Marketing Authorization | Present |
| Apixaban | B01AF | Other Antithrombotic Agents | Marketing Authorization | Present |
| Gadopentetic acid | V08CA | Paramagnetic Contrast Media | Marketing Authorization | Present |
| Cabazitaxel | L01CD | Taxanes | Marketing Authorization | Present |
| Piperacillin + Tazobactam | J01CR | Piperacillin and Enzyme Inhibitor | Bringing dossier into the EEU complience | Present |
| Cefoperazone+Sulbactam | J01DD | Third-generation cephalosporins | Bringing dossier into the EEU complience | Present |
| Ticagrelor | B01AC | Platelet aggregation inhibitors excl. Heparin | Bioequivalence CT | Present |
| Diacerein | M01AX | Other Antiinfl./Antirheumatic Agents, Non-Steroids | Bioequivalence CT | Present |
| Terizidone | J04AK | Other Drugs For Treatment Of Tuberculosis | Bioequivalence CT | Present |
| Dolutegravir+Rilpivirine | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | Present |
| Glecaprevir+Pibrentasvir | J05AP | Antivirals For Treatment Of Hcv Infections | Bioequivalence CT | Present |
| Elbasvir+Grazoprevir | J05AP | Antivirals For Treatment Of Hcv Infections | Bioequivalence CT | Present |
| Dolutegravir+Lamivudine | J05AR | Antivirals for treatment of HIV infections, combination | Bioequivalence CT | Present |
| Rivaroxaban | B01AF | Direct factor Xa inhibitors | Bioequivalence CT | Present |
| Apixaban | B01AF | Direct factor Xa inhibitors | Bioequivalence CT | Present |
CONTACTS
Russia, Moscow.
Multifanctional complex «Federation»
Presnenskaya embankment, 12
East Tower, 27th floor, 17 room.
Phone: + 7 (495) 374-62-84
E-mail: info@pharmrussia.com
© ARS PHARMRUSSIA: CLINICAL & REGULATORY EXPERT CRO, 2009-2024
All rights reserved.